Loading [MathJax]/jax/output/SVG/jax.js
Review

Purinergic P2X7R expressed on regulatory T cells potentially links molecular mimicry to autoimmune responses

  • Received: 20 January 2024 Revised: 16 March 2024 Accepted: 30 April 2024 Published: 16 May 2024
  • The immune system is meant to protect against invading microbes. Although this system is effective against many microbes, some can use molecular mimicry to turn the immune system against the host and activate autoimmune responses. The resulting autoimmunity has significant implications for public health and healthcare costs. It is well known that regulatory T cells (Tregs) are crucial for self-tolerance and that their function is impaired after exposure to self-antigens or antigens with molecular mimicry, leading to the activation of autoimmune responses. How molecular mimicry disrupts Tregs in this manner remains under debate. This review contributes to the field of the pathogenesis of autoimmunity by proposing that purinergic signaling in the lymph nodes, with extracellular ATP, ADP, and adenosine as ligands, plays a pivotal role in this process. Repeated or high-dose microbial infection causes the release of large amounts of extracellular ATP sufficient to reach the threshold of extracellular ATP levels for activating P2X7 purinergic receptors (P2X7Rs) on dendritic cells and Tregs. This hampers the ability of Tregs to suppress autoimmune responses. Crucially, P2X7Rs are activated at very high extracellular ATP levels, thus only after repeated or high-dose infection with microbes. Arguably, in contrast to the rapid elimination of microbes with foreign antigens, the clearance of invading microbes that employ molecular mimicry requires the activation of P2X7Rs at the expense of self-tolerance. Because all processes required to activate autoimmune responses occur in secondary lymphoid organs, this article hypothesizes that, contrary to current convention, microbes do not need to enter organs to initiate autoimmunity. However, some types of microbes can prevent P2X7R-induced Treg disruption by converting extracellular ATP to adenosine, mitigating autoimmune responses resulting in chronic diseases with less severe inflammation. The proposed hypothesized mechanism has potential implications for the understanding and treatment of autoimmune disorders.

    Citation: Djo Hasan. Purinergic P2X7R expressed on regulatory T cells potentially links molecular mimicry to autoimmune responses[J]. AIMS Allergy and Immunology, 2024, 8(2): 80-123. doi: 10.3934/Allergy.2024006

    Related Papers:

    [1] Christian Cortés García . Bifurcations in a discontinuous Leslie-Gower model with harvesting and alternative food for predators and constant prey refuge at low density. Mathematical Biosciences and Engineering, 2022, 19(12): 14029-14055. doi: 10.3934/mbe.2022653
    [2] Jinxing Zhao, Yuanfu Shao . Bifurcations of a prey-predator system with fear, refuge and additional food. Mathematical Biosciences and Engineering, 2023, 20(2): 3700-3720. doi: 10.3934/mbe.2023173
    [3] Peter A. Braza . A dominant predator, a predator, and a prey. Mathematical Biosciences and Engineering, 2008, 5(1): 61-73. doi: 10.3934/mbe.2008.5.61
    [4] Yuanfu Shao . Bifurcations of a delayed predator-prey system with fear, refuge for prey and additional food for predator. Mathematical Biosciences and Engineering, 2023, 20(4): 7429-7452. doi: 10.3934/mbe.2023322
    [5] Shuangte Wang, Hengguo Yu . Stability and bifurcation analysis of the Bazykin's predator-prey ecosystem with Holling type Ⅱ functional response. Mathematical Biosciences and Engineering, 2021, 18(6): 7877-7918. doi: 10.3934/mbe.2021391
    [6] Hongqiuxue Wu, Zhong Li, Mengxin He . Dynamic analysis of a Leslie-Gower predator-prey model with the fear effect and nonlinear harvesting. Mathematical Biosciences and Engineering, 2023, 20(10): 18592-18629. doi: 10.3934/mbe.2023825
    [7] Rajalakshmi Manoharan, Reenu Rani, Ali Moussaoui . Predator-prey dynamics with refuge, alternate food, and harvesting strategies in a patchy habitat. Mathematical Biosciences and Engineering, 2025, 22(4): 810-845. doi: 10.3934/mbe.2025029
    [8] Weijie Lu, Yonghui Xia, Yuzhen Bai . Periodic solution of a stage-structured predator-prey model incorporating prey refuge. Mathematical Biosciences and Engineering, 2020, 17(4): 3160-3174. doi: 10.3934/mbe.2020179
    [9] Tingting Ma, Xinzhu Meng . Global analysis and Hopf-bifurcation in a cross-diffusion prey-predator system with fear effect and predator cannibalism. Mathematical Biosciences and Engineering, 2022, 19(6): 6040-6071. doi: 10.3934/mbe.2022282
    [10] Rongjie Yu, Hengguo Yu, Chuanjun Dai, Zengling Ma, Qi Wang, Min Zhao . Bifurcation analysis of Leslie-Gower predator-prey system with harvesting and fear effect. Mathematical Biosciences and Engineering, 2023, 20(10): 18267-18300. doi: 10.3934/mbe.2023812
  • The immune system is meant to protect against invading microbes. Although this system is effective against many microbes, some can use molecular mimicry to turn the immune system against the host and activate autoimmune responses. The resulting autoimmunity has significant implications for public health and healthcare costs. It is well known that regulatory T cells (Tregs) are crucial for self-tolerance and that their function is impaired after exposure to self-antigens or antigens with molecular mimicry, leading to the activation of autoimmune responses. How molecular mimicry disrupts Tregs in this manner remains under debate. This review contributes to the field of the pathogenesis of autoimmunity by proposing that purinergic signaling in the lymph nodes, with extracellular ATP, ADP, and adenosine as ligands, plays a pivotal role in this process. Repeated or high-dose microbial infection causes the release of large amounts of extracellular ATP sufficient to reach the threshold of extracellular ATP levels for activating P2X7 purinergic receptors (P2X7Rs) on dendritic cells and Tregs. This hampers the ability of Tregs to suppress autoimmune responses. Crucially, P2X7Rs are activated at very high extracellular ATP levels, thus only after repeated or high-dose infection with microbes. Arguably, in contrast to the rapid elimination of microbes with foreign antigens, the clearance of invading microbes that employ molecular mimicry requires the activation of P2X7Rs at the expense of self-tolerance. Because all processes required to activate autoimmune responses occur in secondary lymphoid organs, this article hypothesizes that, contrary to current convention, microbes do not need to enter organs to initiate autoimmunity. However, some types of microbes can prevent P2X7R-induced Treg disruption by converting extracellular ATP to adenosine, mitigating autoimmune responses resulting in chronic diseases with less severe inflammation. The proposed hypothesized mechanism has potential implications for the understanding and treatment of autoimmune disorders.



    The predator-prey model is a model in biomathematics used, and modified, by many researchers to describe the dynamics between a prey and predator species in order to determine conditions in their parameters that allow for either the conservation or extinction of one or both species, where such models are generally posed by systems of ordinary [1,2,3,4,5] or partial differential equations [6,7,8,9,10].

    In particular, the Leslie-Gower models assumes that the intrinsic growth of both species is described by logistic functions, whose carrying capacity between prey and predators is subject to the capacity of the environment or directly proportional to the population size of the prey, respectively [11]. Similarly, this model assumes a functional response of the predator that is generally described by Holling-type functions [12,13,14,15,16].

    For example, assuming that the predator response functional is given by a Holling Ⅱ function f(x)=axx+d [17,18,19], where a>0 is the maximum per capita consumption rate of predators, and 0<d<K is the semi-saturating rate of capture, where predators can be harvested [20,21], the dynamics of population sizes of prey x(t)0 and predators y(t)0 is given by

    {˙x=rx(1xK)axyx+d˙y=sy[1ynx+c]qEy, (1.1)

    where K>0 is the carrying capacity of prey in the environment, which normally determines the resources available for prey survival, n>0 is the quantity of prey consumed by the predator and converted into new births, q>0 is the catchability coefficient, E>0 is the harvesting efforty, and r,s>0 are the intrinsic birth rates of prey and predators, respectively. In particular, if the diet of predators is based exclusively on prey consumption, then c=0 [22,23,24]; otherwise, c>0 describes the alternative food for predators, so their diet is not based exclusively on prey consumption [25,26].

    However, given the existence of prey that take refuge from the predator to subsist in the environment [1,29,30,31,32], and whose intrinsic growth is subject to an auxiliary parameter b>0 (half-saturation) that affects the hyperbolic function of the per capita birth rate curve of the prey [27,28], in addition to the maximum birth rate r>0, then model (1.1) is modified by

    {˙x=rxx+b(1xK)a(xP)y(xP)+d˙y=sy[1yn(xP)+c]qEy, (1.2)

    where P<K is the population size of refugia in prey. In particular, the intrinsic growth of prey approximates logistic growth for a large x; however, if x is small, the parameter b>0 influences its dynamics, of which it may represent examples such as inbreeding, ease of reproduction, difficulty in finding mates, or mating resistance at low temperatures.

    Observe that the model (1.2) is used if the initial prey population size is above the critical refuge population size, that is, if P<x(0). For the case where x(0)<P, the entire prey population size is refugeed from the predator whenever x<P, so there is no interaction between the two species and, hence, the functional response of the predator is deactivated when x<P. In this case, the dynamics of the prey is described by a logistic differential equation ˙x=rx(1xK) for the case in which there are either no external factors inhibiting its growth, or by an autonomous differential equation ˙x=rxx+b(1xK), until they exceed their critical refuge population size and the quantity xP becomes susceptible to predator consumption.

    On the other hand, if the predator's diet is based only on the consumption of prey, they are forced to change their diet due to the deficit of prey in order to survive in the environment [33,34,35], so the model (1.2) should be modified by

    Z0(x,y):{˙x=rxx+b(1xK)aϵ(xP)y(xP)+d˙y=sy[1ynϵ(xP)+(1ϵ)c]qEy, (1.3)

    with

    ϵ={1,ifx>P0,ifx<P. (1.4)

    However, if the predator's diet is not based exclusively on prey consumption, but has equal probability of consumption with the alternative food provided in the environment, the predator's diet is not affected and depends only on the alternative food provided by the environment in the absence of prey. In this case, the model (1.2) is modified by

    Zc(x,y):{˙x=rxx+b(1xK)aϵ(xP)y(xP)+d˙y=sy[1ynϵ(xP)+c]qEy, (1.5)

    with ϵ as described in (1.4).

    Consequently, and given the possible scenarios for predator growth and survival at low and high prey densities subject to their refuge, the objective of this paper is to perform a qualitative and bifurcation analyses to models (1.3) and (1.5), as shown in Sections 2 and 3, respectively, to determine similarities or difference in both models.

    Let x(t)0 and y(t)0 be considered as the population sizes of prey and predators, respectively, whose dynamics are given by the model (1.3), defined in the biological sense region

    Ω={(x,y)R2:0xK,0yM} (2.1)

    with M=max{n(KP),c}. In particular, the vector fields of the model (1.3) are given by

    Z0(x,y)={X(x,y)=(rxx+b(1xK)a(xP)y(xP)+dsy[1yn(xP)]qEy),x>PY(x,y)=(rxx+b(1xK)sy(1yc)qEy),x<P (2.2)

    where X and Y are defined in Σ+={(x,y)Ω:P<xK} and Σ={(x,y)Ω:0<x<P}, respectively.

    Since the model (2.2) is equivalent to a Filippov system [36,37,38,39], if f(x,y)=xP, Xf(p)=X(p),gradf(p) and Yf(p)=Y(p),gradf(p), then Xf(p)=Yf(p)=rPP+b(1PK)>0 for all pΣ={(x,y)Ω:x=P}. Therefore, since the vector field Y is composed of a system of autonomous and independent differential equations, the trajectories φZ0 with initial condition (x(0),y(0))Σ must cross Σ and remain in Σ+. Additionally, φZ0 with the initial condition p=(P,y(0))Σ is defined as φZ0(p,t)=φX(p,t) for all tI{t>0} and φZ0(p,t)=φY(p,t) for tI{t0}.

    Lemma 1. For an arbitrary initial condition (x(0),y(0))Ω, the model (2.2) has a unique φZ0 trajectory and remains in Ω.

    Proof. Since the vector fields X and Y are continuously differential and the trajectories φZ0 cross Σ or remain Σ+ for all initial conditions (x(0),y(0))Σ or (x(0),y(0))Σ+, by the existence and uniqueness theorem [40] for every vector field the uniqueness of the trajectories are guaranteed. Additionally, for all 0x<P, if x=0 then ˙x=0 for all y0. Similarly, if y=0, then ˙y=0, and if y=M, we have that ˙y0. Thus, the trajectories φZ0 do not cross Σ. Moreover, for all P<xK, if x=K, then ˙x=0; if y=0, then ˙y=0; and if y=n(KL)+c, then ˙y0, so φZ0 does not cross Σ+. The dynamics of the model at points (P,0) and (P,M) do not cross Ω and remain to be analyzed. In this case, since the trajectories φZ0 with the initial condition (x(0),y(0))ΣΣ+ cross Σ, we have that the trajectories φZ0 do not escape from the points (P,0) and (P,M).

    The equilibria in the model (2.2) over the coordinate axes are given by P0=(0,0)Σ, P1=(K,0)Σ+, and P2=(0,c(sqE)s)Σ if sqE>0. The local stability of the equilibria is summarized in the following result.

    Lemma 2. If sqE<0, then P0 and P1 are saddle points. If sqE>0, then P0 is a locally unstable node, P1 a locally stable node and P2 is a saddle point.

    Proof. The local stability of P1Σ+ and P0,P2Σ are guaranteed from the computation of the eigenvalues of the Jacobian matrix DX of the vector field X computed in P1Σ+ and of the Jacobian matrix DY of the vector field Y computed in P0,P2Σ.

    On the other hand, since the vector field Y has no interior equilibria, the intersections in Σ+ of nullclines

    y=f1(x):=nx(sqE)snP(sqE)s,y=f2(x):=rx(Pdx)(xK)aK(xP)(x+b), (2.3)

    are defined in the vector field X, and determine the number of interior equilibria in the model (2.2). In particular, note that the model (2.2) has no interior equilibria if sqE<0 since the nullclines (2.3) do not intersect in Σ+.

    For sqE>0, the possible positive roots of the polynomial

    Q(x)=Ax3+Bx2+Cx+D, (2.4)

    with

    A=rs+aKn(sqE)>0,B=rs(dKP)+aKn(b2P)(sqE),C=K[anP(2bP)(sqE)+rs(dP)],D=abnKP2(sqE)>0, (2.5)

    determine the number of interior equilibria in the model (2.2).

    The following result shows the existence of a unique interior equilibrium P3=(x,y) in the model (2.2), with x as the positive root of the polynomial (2.5) and y=f1(x), as observed in Figure 1.

    Figure 1.  Nullclines (2.3) with sqE>0. The green and margenta curves represent the nullclines y=f1(x) and y=f2(x), respectively. The brown and black dotted lines are x=Pd and x=P, respectively.

    Lemma 3. If sqE>0, the model (2.2) has a unique interior equilibrium P3.

    Proof. By Descartes' sign criterion, we have that the polynomial Q(x) (2.4) must have two positive roots: x and x+. However, since y=f1(x) is a straight line with a positive slope and intercept at (P,0), f2(x) when x± and f2(x)± for xP±, and by constraint, we have that x+<P and P<x. Therefore, the model (2.2) has a unique interior equilibrium.

    The local dynamics of the interior equilibrium P3 remain to be analyzed. In this case, since Ω is invariant and the equilibria P0, P1, and P2 are unstable, by the Poincare - Bendixson Theorem [41,42] we have that P3 cannot be a local saddle point, that is, det DX(P3)>0, with DX the Jacobian matrix of the vector field X computed in P3.

    On the other hand, the sign of the trace in the Jacobian matrix DX of the vector field X computed in P3, with

    tr DX(P3)=br(b+K)K(x+b)2+ad2n(sqE)s(x+dP)2adn(sqE)s(x+dP)(sqE)rK,

    which determines the local stability of the equilibrium P3, and is summarized in the following result. In particular, if P3 is locally unstable, by the Poincare -Bendixson Theorem it guarantees the existence of at least one stable ΓX limit cycle in Σ+, which does not collide with Σ.

    Lemma 4. For sqE>0 and :=[trDX(P3)]24detDX(P3)<0, then P3 is either a locally stable or unstable focus if trDX(P3)<0 or 0<trDX(P3), respectively. For sqE>0 and :=[trDX(P3)]24detDX(P3)>0, then P3 is either a locally stable or unstable node if trDX(P3)<0 or 0<trDX(P3), respectively.

    In the first instance, the following result shows conditions on the model parameters (2.2) for which guarantees the global stability of P1.

    Theorem 1. If sqE<0, then P1 is globally asymptotically stable in Ω.

    Proof. Since P0 is a saddle point, P2,P3Ω and ˙y=(sqE)ysy2n(xP)<0 for all (x,y)Σ+, then the model (2.2) has no limit cycles in Σ+. Furthermore, since the model (2.2) has no interior equilibria and no limit cycles in Σ, and the differential equations describing the vector field Y are autonomous and independent, all trajectories φZ0 with initial condition (x(0),y(0))Σ cross Σ and remain in Σ+, so the trajectories φZ0 converge to P1.

    On the other hand, by using the Bendixon-Dilac [40] criterion on the model (2.2), the following result shows a first sufficient condition on the model parameters (2.2) for which guarantees the global stability of P3.

    Theorem 2. If sqE>0 and b(b+P)<(b+K)(dP), then P3 is globally asymptotically stable in Ω.

    Proof. If

    g1(x,y)=rxx+b(1xK)a(xP)y(xP)+d,g2(x,y)=sy[1yn(xP)]qEy, (2.6)

    are functions describing the vector field X in Σ+, and

    h(x,y)=(xP)+dxy

    is a Dirac function, then

    hg1x(x,y)+hg2y(x,y)={αryK(x+b)2+aPx2+rKy+s[(xP)+d]nx(xP)}<0

    with α=b(dKP)+K(dP)b2>0 for all (x,y)Σ+, so the model (2.2) has no limit cycles in Σ+. Therefore, and analogous to the proof of Theorem 1, we have that P3 is globally asymptotically stable in Ω.

    From the Lyapunov criterion [40], the following result shows a second sufficient condition on the parameters of the model (2.2) for which the global stability of P3 is guaranteed in Ω.

    Theorem 3. If sqE>0 and d+2P>K, the equilibrium P3 is globally asymptotically stable in Ω.

    Proof. Similarly to what we proved in Theorem 1, it is sufficient to prove that P3 is globally asymptotically stable in Σ+. Indeed, if

    V(x,y)=xxux(uP)ρ(u)du+1sqEyyvyvdv

    for all (x,y)Σ+ and ρ(x)=a(xP)(xP)+d is a Lyapunov function, g(x)=rxx+b(1xK)ρ(x) and (2.3), we have that

    ˙V=xx(xP)ρ(x)˙x+yyy(sqE)˙y=xxxP[rxx+b(1xK)ρ(x)y]+yysqE[s(1yn(xP))qE]=xxxP[rxx+b(1xK)ρ(x)y](xx)(yy)xP+yysqE[syn(xP)syn(xP)]=xxxP[g(x)g(x)](xx)(yy)xP+s(yy)sqE[(yy)P+xyxyn(xP)(xP)]=xxxP[g(x)g(x)](xx)(yy)xP+yyy[(yy)P+xyxyxP]=xxxP[g(x)g(x)](xx)(yy)xP+(yy)2y[y(xx)(yy)(xP)xP]=xxxP[g(x)g(x)](xP)(yy)2y(xP)=1xP{(xx)[g(x)g(x)]s(yy)2n(sqE)}.

    Since P<x, a sufficient condition for ˙V<0 is to prove that g(x) is non-increasing. Indeed, by substituting ˉx=xP, then

    g(ˉx)=r(ˉx+P)(ˉx+d)(KˉxP)aKˉx(ˉx+P+b)

    and so

    g(ˉx)=r{ˉx+2ˉx(b+P)+ˉx[βb+d(KP)+P]+2dPˉx(KP)+d(b+P)(KP)}aˉx2K(ˉx+b+P)2<0,

    with β=dK+2P>0.

    In the first instance, the model (2.2) has a Hopf bifurcation if tr DX(P3)=0, as observed in the following result. In particular, and as observed in Lemma 4, if tr DX(P3)<0, then P3 is unstable with at least one stable limit cycle ΓX around P3, where ΓX collides with P3 if tr DX(P3)=0. However, if tr DX(P3)>0, then P3 is stable.

    Theorem 4. The model (2.2) has a Hopf bifurcation around P3 if trDX(P3)=0.

    Proof. Since

    tr DX(P3)a=dn(sqE)(xP)s(x+dP)2<0,

    the transversality condition for existence of the Hopf bifurcation is guaranteed [43].

    Moreover, the model (2.2) has a transcritical bifurcation when sqE=0, as summarized by the following result. In this case, if sqE>0, then P3Σ+ and P1 is a saddle point. For sqE=0, P3 collides with P1, so P1 is a stable saddle-node equilibrium since det DX(P1)=0 and tr DX(P1)=r<0. However, if sqE<0, then P3Σ+, and P1 is locally stable.

    Theorem 5. The model (2.2) has a transcritical bifurcation around P1 if sqE=0.

    Proof. Let Xs(x,y,s)=(0,y(1yn(xP)))T be the derivative of the vector field X(x,y,s) with respect to s, U=(a(KP)(b+K)r(d+KP),1)T is the eigenvector associated with the null eigenvalue in the Jacobian matrix DX calculated in P1, and W=(0,1)T is the eigenvector associated with the null eigenvalue in the Jacobian matrix DXT calculated in P1.

    If s=s0:=qE, by the transcritical bifurcation theorem [44], three conditions must be guaranteed: WTXs(P1,s0)=0, WT[DXs(P1,s0)U]0, and WT[D2X(P1,s0)(U,U)]0. Indeed,

    ● Since Xs(P1,s0)=(0,0)T, then WTXs(P1,s0)=0.

    ● Since DXs(P1,s0)U=(0,1)T, then WT[DXs(P1,s0)U]=1>0.

    ● If X=(g1(x,y,s),g2(x,y,s))T, with g1 and g2 as described in (2.6), and U=(u1,u2), then

    D2X(P1,s0)(U,U)=(2g1x2u1u1+22g1xyu1u2+2g1y2u2u22g2x2u1u1+22g2xyu1u2+2g2y2u2u2)=(2a2(KP)[bdPb(KP)2+dK2]rK(d+KP)32s0n(KP)),

    and so WT[D2f(P1,s0)(U,U)]=2s0n(KP)>0.

    To conclude, and as shown in Lemmas 2 and 4, Figure 2 shows the bifurcation diagram of the model (2.2) in the plane (P,E), realized by the numerical bifurcation package SlideCont [45], whose selected fixed parameters were chosen in order to show all possible dynamics of the model (2.2) in the bifurcation plane (P,E).

    Figure 2.  Bifurcation diagram of the model (2.2) in the plane (P,E) with fixed parameters: a=0.3, b=3, c=r=0.5, d=0.001, K=2, n=2.8, q=1 and s=0.1. Dotted line: =0. The Normal and dash dotted lines represent the Hodf and Transcritical bifurcation, respectively. Region Ⅰ: P2,P3Σ+ and P1 globally asymptotically stable. Region Ⅱa: P2,P3Σ+ with P3 globally asymptotically stable node. Region Ⅱb: P2,P3Σ+ with P3 globally asymptotically stable focus. Region Ⅲ: P2,P3Σ+ with P3 unstable focus and ΓX a globally asymptotically stable limit cycle.

    In particular, since the trajectories φX and φY in the model (2.2) do not collide in Σ, that is, the trajectories φZ0 with initial condition (x(0),y(0))Σ must cross Σ and remain in Σ+, the phase portraits characterizing each bifurcation region, shown in Figures 3, are drawn by the two vector fields X and Y, separated by the straight line x=P, and simulated in Matlab [46], where Y can be defined for all xP because the trajectory φZ0 with initial condition p=(P,y(0))Σ is defined as φZ0(p,t)=φX(p,t) for all tI{t>0} and φZ0(p,t)=φY(p,t) for tI{t0}. The bifurcation regions are described below.

    Figure 3.  Dynamics of the model (2.2) characterizing each bifurcation region shown in Figure 3. The vector fields X and Y are represented by blue and orange colors, respectively, and Σ is the black dashed line. Margenta curve: stable limit cycle ΓX around P3. Red point: P0. Pink point: P1. Blue point: P2. Black point: P3.

    ● If sqE<0, represented in region Ⅰ, the model (2.2) has no interior equilibria, so the φZ0 trajectories converge to equilibrium P1, as observed in Figure 3(b). However, if sqE>0, then P3Ω, as observed in regions Ⅱa, IIb and Ⅲ. Note that the transcritical bifurcation separates region Ⅰ from regions Ⅱa, IIb, and Ⅲ.

    ● In regions Ⅱa and IIb we have that P3 is a stable node or focus, as observed in Figures 3(c, d), respectively. In both regions, the trajectories φZ0 converge to the equilibrium P3. Moreover, the curve =0 separates regions Ⅱa and IIb.

    ● The model (2.2) has a stable limit cycle ΓX in Σ+, characterized in region Ⅲ, and which will not collide with Σ. Moreover, P3 is unstable, so the φZ0 trajectories converge to ΓX, as observed in Figure 3(e). In particular, the Hopf bifurcation separates region Ⅲ from regions Ⅱa and IIb.

    Let x(t)0 and y(t)0 be the population size of prey and predators, respectively, whose dynamics are given by the model (1.5) in the biological sense region:

    ˜Ω={(x,y)R2:0xK,0yn(KP)+c}. (3.1)

    In this case, the vector field of the model (1.5) is given by

    Zc(x,y)={˜X(x,y)=(rxx+b(1xK)a(xP)y(xP)+bsy[1yn(xP)+c]qEy),x>PY(x,y)=(rxx+b(1xK)sy(1yc)qEy),x<P (3.2)

    where the vector fields ˜X and Y are defined in ˜Σ+={(x,y)˜Ω:P<xK} and ˜Σ={(x,y)˜Ω:0x<P}, respectively.

    If ˜Σ={(x,y)˜Ω:x=P} and similarly to the dynamics of the model (2.2) in Σ, the trajectories φZc with initial condition p=(P,y)˜Σ is defined as φZc(p,t)=φ˜X(p,t) for tI{t>0} and φZc(p,t)=φY(p,t) for tI{t0} because ˜Xf(p)=Yf(p)=rP(1PK)>0.

    Analogous to the proof shown in Lemma 1, some results are guaranteed in the model (3.2).

    Lemma 5. ˜Ω is an invariant set and the trajectory (x(0),y(0))˜Ω exists and is unique.

    The equilibria of the model (3.2) on the coordinate axes (x,y) is given by P0,P2˜Σ, and ˜P1=(K,0)˜Σ+, where P0 and P2 are equivalent to the equilibria of the model (2.2), so that their local stability is described in Lemma 2. In addition, and equivalently to what is shown in Lemma 2, ˜P1 is either a locally stable node or saddle point if sqE<0 or sqE>0, respectively.

    On the other hand, the intersections in the nullclines of the vector field ˜X in ˜Σ+

    y=f2(x),y=f3(x):=nx(sqE)s(sqE)(nPc)s, (3.3)

    with y=f2(x) as represented in (2.3), and y=f3(x) a line with slope nx(sqE)s and intercept at (0,(sqE)(nPc)s) and (nPcn,0), determine the number of interior equilibria of the model (3.2), equivalent to determining the positive roots of the polynomial

    ˜Q(x)=˜Ax3+˜Bx2+˜Cx+˜D, (3.4)

    with

    ˜A=rs+aKn(sqE)>0,˜B=rs(dKP)+aKn(bn2nP+c)(sqE),˜C=K[ab(2nPP)+aP(cnP)](sqE)rsK(dP),˜D=abP(cnP)(sqE). (3.5)

    In this case, it is evident that the nullclines (3.3) do not intersect at ˜Σ+ if sqE<0. Similarly, if sqE>0 and nPc>0, it follows that there is a unique point of the intersection at the nullclines (3.3) in ˜Σ+, which corresponds to a unique interior equilibrium ˜P=(x1,y1)˜Σ+ in the model (3.2), with y1=f3(x1), as observed in Figure 4, and whose proof is analogous to what is shown in Lemma 3.

    Figure 4.  Nullclines (3.3) with sqE>0. Margenta and turquoise curves are the nullclines y=f2(x) and y=f3(x), respectively. Brown and dark cyan dotted lines are x=Pd and x=nPcn, respectivaly. Dotted black line is x=P.

    Lemma 6. If sqE<0, the model (3.2) has no interior equilibria. If sqE>0 and nPc>0, the model (3.2) has only one equilibrium.

    On the other hand, if sqE>0 and nPc<0, then y1=f3(x1)>0 for all x1>0, so the positive roots of the polynomial (3.4) are interior equilibria of the model (3.2). In this case, assuming that ˜P=(x1,y1) is an interior equilibrium that always exists in ˜Ω with sqE>0 and nPc<0, a division between the polynomial ˜Q(x) (3.4) and x1 leads to the polynomial

    ˉQ(x)=˜Ax2+(˜B+˜Ax1)x+˜C+x(˜B+˜Ax1) (3.6)

    as a factor of ˜Q(x) and the rest of the division is ˜Q(x1)=0.

    By clearing ˜B+˜Ax1 from (3.4) and substituting it in (3.6), we have

    ˉQ(x)=˜Ax2+(˜B+˜Ax1)x˜Dx1. (3.7)

    If sqE>0 and nPc<0, then the following result shows conditions on the coefficients of the polynomial ˉQ(x) that determine the number of interior equilibria in the model (3.2).

    Lemma 7. Let sqE>0, nPc<0 and ˜=(˜B+˜Ax1)2+4˜A˜Dx1.

    1) If ˜<0, the model (3.2) has only one interior equilibrium.

    2) If ˜=0, the model (3.2) has two interior equilibria.

    3) For ˜>0,

    (a) If ˜B+˜Ax1<0, the model (3.2) has three interior equilibria.

    (b) If ˜B+˜Ax10, the model (3.2) has only one interior equilibrium.

    In particular, if the model (3.2) has a unique interior equilibrium point ˜P, and since ˜Ω is an invariant with equilibria on the unstable coordinate axes, by constraint, we have that ˜P must be locally either a node or a focus, stable or unstable, so its local stability result is equivalent to what is shown in Lemma 4, where the trace in the Jacobian matrix D˜X computed on ˜P is given by:

    tr D˜X(˜P)=br(b+K)K(x1+b)2ad(cnd)(sqE)s(x1+dP)2adn(sqE)s(x1+dP)(sqE)rK. (3.8)

    On the other hand, if the model (3.2) has three different interior equilibria ˜P3=(x1,g3(x1)), ˜P4=(x,g3(x)) and ˜P5=(x+,g3(x+)), with x1<x<x+, the eigenvalues of the Jacobian matrix D˜X computed at each interior equilibrium ˜Pi,i=3,4,5, shows that ˜P4 is a saddle point; therefore, ˜P3 and ˜P5 must be locally stable or unstable nodes and/or focus, as summarized by the following result.

    Lemma 8. If the model (3.2) has three different interior equilibriums ˜P3=(x1,f3(x1)), ˜P4=(x,f3(x)), and ˜P5=(x+,f3(x+)), with x1<x<x+, then ˜P4 is a saddle point.

    For the case of local stability of the equilibria ˜P3 and ˜P5, the following section generalizes the cases of local stability for both equilibria.

    Let us consider the case where the model (3.2) has three interior equilibria ˜P3, ˜P4, and ˜P5, with ˜P3 stable and Ws+(˜P4), Wu+(˜P4) the upper stable and unstable varieties to the right in ˜Σ+ of the saddle point ˜P4, respectively, and whose dynamics is observed in Figure 5.

    Figure 5.  Relative positions of the varieties W+u(˜P4) and W+s(˜P4), with red and blue curves are W+u(˜P4) and W+s(˜P4), respectively. Margenta and turquoise curves are the nullclines (3.3) as shown in Figure 4.

    In this case, since ω-limit of Wu+(˜P4) could be the equilibrium ˜P5, when locally stable, or a stable limit cycle surrounding ˜P5 when locally unstable, or the equilibrium ˜P3 as observed in Figure 5, if (˜x0,˜ya)Wu+(˜P4) and (˜x0,˜yb)Ws+(˜P4), with P<˜x0<K, ˜ya=˜f1(a,b,c,d,E,K,P,q,r,s) and ˜yb=˜f2(a,b,c,d,E,K,P,q,r,s) continuous functions in X, then there exist (˜x0,˜ya),(˜xo,˜yb)˜Σ+ such that ˜ya=˜yb; therefore, the varieties Wu+(˜P4) and Ws+(˜P4) intersect and form a homoclinic curve ˜γ created by ˜P4 and surrounding ˜P5 as shown in the following result.

    Theorem 6. If ˜P3 is stable and Ws+(˜P4)Wu+(˜P4), then the model (3.2) has a homoclinic curve ˜γ surrounding ˜P5.

    In particular, since the trace of DX is calculated in the equilibria ˜P3, ˜P5 is equivalent to that shown in (3.8), replacing x1 by x or x+, respectively, the following result shows a generalization about the local stability of the equilibria ˜P3 and ˜P5.

    Theorem 7. If ˜P3 is unstable, that is, trD˜X(˜P3)>0, then

    1) ˜P5 is stable if trD˜X(˜P5)<0.

    2) ˜P5 is unstable if trD˜X(˜P5)>0. In this case, at least one stable cycle is formed surrounding ˜P3, ˜P4, and ˜P5.

    For ˜P3 stable, that is, trD˜X(˜P3)<0,

    1) If ˜yb<˜ya,

    (a) ˜P5 is unstable if trD˜X(˜P5)>0

    b) ˜P5 is stable if trD˜X(˜P5)<0. In this case, at least one unstable cycle is formed, surrounding ˜P5.

    2) If ˜yb>˜ya, ˜P5 is a stable node or focus.

    In addition, if ˉ(˜Pi):=[trD˜X(˜Pi)]24detD˜X(˜Pi), i=3,5, then ˜Pi is locally a node or a focus if ˉ(˜Pi)>0 or ˉ(˜Pi)<0, respectively.

    Proof. The Theorem is immediate in view of the results shown in Lemma 4 and the Poincare - Bendixson Theorem [40]. Moreover, since there is a stable limit cycle surrounding the equilibrium ˜P3, this cycle increases until it coincides with the homoclinic curve ˜γ that joins the equilibrium ˜P2. Upon breaking ˜γ, that is, if ˜yb<˜ya, the local stability of ˜P3 is not altered.

    In the first instance, if ˜P is a locally non saddle point equilibrium, then the model (3.2) has a Hopf bifurcation if tr D˜X(˜P)<0, the proof of which is analogous to what is shown in Theorem 4. Similarly, the model (3.2) has a transcritical bifurcation if sqE=0, that is, when the equilibrium ˜P collides with ˜P1, and whose proof is similar to that shown in Theorem 4, so it is omitted for brevity. On the other hand, since the model (3.2) has a homoclinic curve ˜γ if ˜P3 is unstable and the varieties Ws+(˜P4) and Wu+(˜P4) intersect, then such a model has a homoclinic bifurcation as shown in the following result, the proof of which is deduced from Theorems 6 and 7.

    Theorem 8. If the model (3.2) has three interior equilibria ˜P3, ˜P4 and ˜P5, with ˜P3 stable and ˜ya˜yb=0, the model (3.2) has a homoclinic bifurcation.

    Finally, if ˜P3,˜P4,˜P5˜Ω, the model (3.2) has a saddle-node bifurcation if the saddle point ˜P4 collides with ˜P3 or ˜P5, forming the saddle-node equilibria ˜P+=(˜x+,f2(˜x+)) with ˜x+=˜B+˜Ax12˜A or ˜P=(˜x,f3(˜x)) with ˜x=x, as observed in the following result. In particular, given that the Jacobian matrix D˜X in the vector field ˜X of the model (3.2) calculated in ˜P+ is

    D˜X(˜P+)=[an(sqE)(˜x+P)s[(˜x+P)+d]a(˜x+P)(˜x+P)+dn(sqE)2s(sqE)], (3.9)

    with det D˜X(˜P+)=0 and

    tr D˜X(˜P+)=an(sqE)(˜x+P)s[(˜x+P)+d](sqE),

    then ˜P+ is a stable or unstable saddle-node equilibrium if tr DX(˜P+)<0 or tr DX(˜P+)>0, respectively. Analogously for ˜P if ˜x+ is replaced by ˜x.

    Theorem 9. If ˜P3 and ˜P4, or ˜P5 and ˜P4, collide, the model (3.2) has a saddle-node bifurcation around ˜P+ o ˜P, respectively.

    Proof. The case in which ˜P4 collides with ˜P5 will be proved, similarly for the case in which ˜P3 and ˜P4 collide. Let ˜Xc(x,y,c) be the derivative of the vector field ˜X(x,y,c) with respect to c, that is, ˜Xc(x,y,c)=(0,sy2[n(xP)+c]2)T, and U=(sn(sqE),1)T, W=((sqE)[(˜x+P)+d]a(˜x+P),1) the eigenvectors associated with the null eigenvalue in D˜X and D˜XT calculated in ˜P+, respectively.

    If c0 satisface ˜(c0)=0, by the saddle-node bifurcation Theorem [44], two conditions must be guaranteed: WT˜Xc(˜P+,c0)0 and WT[D2˜X(˜P+,c0)(U,U)]0. Indeed,

    1) Since ˜Xc(˜P+,c0)=(0,(sqE)2s)T then WT˜Xc(˜P+,c0)(sqE)2s>0.

    2) If ˜X=(˜g1(x,y,c),˜g2(x,y,c))T, with ˜g1=rxx+b(1xK)a(xP)y(xP)+d and ˜g2=sy[1yn(xP)]qEy, and U=(u1,u2), then

    D2˜X(˜P+,c0)(U,U)=(2˜g1x2u1u1+22˜g1xyu1u2+2˜g1y2u2u22˜g2x2u1u1+22˜g2xyu1u2+2˜g2y2u2u2)=(2s(3˜Ax++˜B)n2K[(˜x+P)+d](sqE)20),

    and WT[D2˜X(˜P+,c0)(U,U)]=2s(3˜A˜x++˜B)n2K[(x+P)+b](sqE)20.

    Figure 6 shows the bifurcation curves in the (P,E) plane, and realized by the numerical bifurcation package SlideCont [45], which the transcritical bifurcation separates regions Ⅰ and Ⅱ, the homoclinic bifurcation separates regions Ⅵ and Ⅶ and the Hopf bifurcation divides regions Ⅱ and Ⅲ, Ⅴ and Ⅵ, and Ⅶ and Ⅷ. In this case, the stability of ˜P, ˜P3 and ˜P5 are altered in the curves separating regions Ⅱ-Ⅲ, Ⅴ-Ⅵ, and Ⅶ-Ⅷ, respectively.

    Figure 6.  Bifurcation diagram of the model (3.2) in the plane (P,E) with fixed parameters: a=0.3, b=3, c=5, d=0.001, K=2, n=2.8, q=1, r=0.5 and s=0.1. Dash dotted line: Transcritical bifurcation. Normal line: Hopf Bifurcation. Dash dot dotted line: Saddle-node bifurcation. Dashed line: Homoclinic bifurcation. Region Ⅰ: P2, ˜P, ˜Pi˜Ω, i=3,4,5, and ˜P1 globally asymptotically stable. Region Ⅱ: P2˜Ω and ˜P˜Ω globally asymptotically stable. Region Ⅲ: P2˜Ω, ˜P˜Ω unstable and existence of a globally asymptotically stable limit cycle Γ˜X around ˜P. Region Ⅳ: P2˜Ω, ˜Pi˜Ω unstables, i=3,4,5, and existence of a globally asymptotically stable limit cycle. Γ˜X around ˜Pi. Region Ⅴ: P2˜Ω, ˜Pi˜Ω, i=3,4,5, with ˜P3 unstable and ˜P5 globally asymptotically stable. Region Ⅵ: P2, ˜Pi˜Ω, i=3,4,5, with ˜P3 and ˜P5 locally asymptotically stable. Region Ⅶ: P2, ˜Pi˜Ω, i=3,4,5, with ˜P3, ˜P5 locally asymptotically stable and an unstable limit cycle Γ˜X around ˜P5. Region Ⅷ: P2, ˜Pi˜Ω, i=3,4,5, with ˜P3 globally asymptotically stable and ˜P5 unstable.

    Furthermore, in regions Ⅴ and Ⅷ, we observe the existence of three interior equilibria in the model (3.2), which the chair-node bifurcation formed between regions Ⅱ and Ⅴ shows the collision of P3 and ˜P4. However, the collision between ˜P4 and ˜P5 is shown by the curve between regions Ⅶ and Ⅷ. Similarly, the curve separating regions Ⅴ and Ⅲ represents a saddle-node bifurcation.

    On the other hand, since the selected fixed parameters were chosen in order to show all possible dynamics of the model (3.2) in the bifurcation plane (P,E) in Figure 6, Figure 7 shows the phase portraits of each bifurcation region, whose dynamics are described as:

    Figure 7.  Dynamics of the model (3.2) describing bifurcation regions Ⅰ to Ⅵ shown in 6. The vector fields ˜X and Y are represented by green and orange colors, respectively, and ˜Σ is the black dashed line. Blue line: φZc. Blue curve: unstable limit cycle Γ˜X. Margenta curve: stable limit cycle Γ˜X. Red point: P0. Blue point: P2. Pink point: ˜P1. Green point: ˜P3. Orange point: ˜P4. Gray point: ˜P5. Black point: ˜P.

    ● Regions Ⅰ-Ⅲ are equivalent to that shown in Figure 2, so there is a single equilibrium ˜P and its local stability is observed in Figures 7(a, b, c).

    ● For the case where ˜P3 and ˜P5 are unstable equilibria, we observe the formation of a limit cycle Γ˜X surrounding the three interior equilibria in region Ⅳ as observed in Figure 7(d), so that the trajectories φZc converge to Γ˜X.

    ● If ˜P3 is unstable and ˜P5 is stable, in region Ⅴ the trajectories φZc converge to ˜P3 as observed in Figure 7(e).

    ● For the case where ˜P3 and ˜P5 are stable, we have either the formation of a locally unstable limit cycle surrounding ˜P5, or a homoclinic curve joining ˜P4 and surrounding ˜P5, or the breaking of such a curve without altering the stability of ˜P5. In this case, in region Ⅶ we have a locally unstable limit cycle as observed in Figure 7(g), which vanishes as shown in region Ⅵ of Figure 7(f).

    ● In region Ⅷ we have that φZc converges to ˜P3 as observed in Figure 7(h).

    Since the predator-prey Leslie-Gower models proposed by several researchers which consider constant prey refuge are valid only when the initial population size of the prey is above their refuge [1,29], that is, when P<x(0), in this paper, we make a general modification to these models in order to show the dynamics of both species without restrictions on the initial condition of the proposed Leslie-Gower models.

    On the other hand, given the hypotheses on the dynamics of predators in the presence or absence of prey for their food, the proposed model (1.3) considers that the predator's diet depends only on prey; in the absence of prey, they are forced to obtain other types of food for their subsistence. However, the model (1.5) considers that the predator's diet is given by prey and alternative food provided by the environment, and in the absence of prey, predators are not forced to change their diet.

    In both proposed models (1.3) and (1.5), all trajectories with initial condition in the vector field Y cross the line x=P, and remain in the vector field X or ˜X, respectively, because the system of differential equations describing the vector field Y are independent and the only stable interior equilibrium does not belong to the biological sense region, though the trajectories try to make a convergence to this point. Similarly, the stable or unstable varieties of each interior equilibrium in both models do not cross the straight line x=P, unlike the unstable variety of P0, which connects to P1 or ˜P1, and P2. Biologically, the growth of the prey described by both models (1.3) and (1.5) cannot be controlled below P>0, so prey growth over time is higher than P.

    The model (1.3) has a unique interior equilibrium point if the intrinsic birth rates of the predators are greater than the product of the catchability coefficient and hasvesting effort of the predators, that is sqE>0; otherwise, the prey converge to their carrying capacity K>0 and the predators become extinct. Moreover, the model (1.3) has a stable limit cycle as long as the interior equilibrium is unstable, so both species stabilize over time if the interior equilibrium is stable. In this model we have two types of bifurcations: Transcritical and Hopf. These are what separates the extinction or not of predators and the long-term stabilization of the population size of both species, respectively.

    The bifurcation cases of model (1.3) can be transferred to model (1.5). However, model (1.5) has two additional bifurcations: saddle-node and homoclinic. In this case, the model can have between one or three interior equilibria as long as sqE>0; otherwise, analogous to model (1.3), predators die out and prey converge to the carrying capacity.

    For the case where model (1.5) has three interior equilibria, there exists a stable limit cycle surrounding all its interior equilibria if ˜P3 and ˜P5 are unstable. Similarly, the model (1.5) could have a locally unstable limit cycle if ˜P3 and ˜P5 are stable, and the homoclinic bifurcation is given by the formation of a homoclinic curve ˜γ given by ˜P4.

    In addition to the homoclinic bifurcation, the model (1.5) could have a heteroclinic bifurcation, whose bifurcation curve coincides with the homoclinic, from which a variety connection transition is made between ˜P1 and ˜P3 or ˜P1 and ˜P5, where the locally unstable limit cycle is given by the formation of the heteroclinic curve connecting ˜P1 and ˜P5.

    On the other hand, if the model (1.5) has a unique interior equilibrium, equivalently to the model (1.3), we have that the growth of both species stabilizes with time, or on the contrary has oscillatory solutions, when the equilibrium is stable or unstable, respectively. However, if the model (1.5) has three interior equilibria, the growth of the prey converges to its minimum quantity, regardless of the initial condition, if ˜P3 is stable and ˜P5 is unstable. However, if ˜P3 and ˜P5 are stable, and there is no unstable cycle surrounding ˜P5, then prey converges to its minimum quantity if the initial condition of the species is above the stable variety of ˜P4, otherwise prey converges to its maximum quantity. Similarly, if the model (1.5) has three equilibria where ˜P3 and ˜P5 are stable, with an unstable cycle surrounding ˜P5, prey converges to its minimum quantity if the initial condition is above the limit cycle.

    Similarly, if the model (1.5) has three interior equilibria, where ˜P3 is unstable and ˜P5 is stable, the prey converge to their maximum quantity regardless of their initial condition. However, if ˜P3 and ˜P5 are unstable, both species have oscillatory solutions. In particular, alternative food for predators could lead to a possible maximum or minimum choice in the amount of prey over time as long as the model (1.5) has three interior equilibria, with appropriate stability for each of these, and an appropriate selection in the initial condition of prey and predators.

    To conclude, if in both proposed models (1.3) and (1.5) no external factors inhibiting the intrinsic growth of prey are considered, that is, if ˙x=rx(1xK) in the absence of predators, the bifurcation cases for the two models (1.3) and (1.5) hold, and the interior equilibria still need to be computed computationally, so the alteration of ˙x=rx(1xK) or ˙x=rxx+b(1xK) in the absence of predators does not affect the overall mathematical results in both proposed models.

    The authors declare they have not used Artificial Intelligence (AI) tools in the creation of this article.

    This research was supported by MCIN/AEI/10.13039/501100011033 through grant BADS, no. PID2019-109320GB-100, and the associated FPI contract PRE2019-088899 to Christian Cortés García. The Spanish MICINN has also funded the "Severo Ochoa" Centers of Excellence to CNB, SEV 2017-0712.

    The author declare there is no conflict of interest.


    Acknowledgments



    I am grateful to Coosje van der Pol, PhD, for her comments on the text and to Olaf PJ Vrooman, MD, for his comments.

    Conflicts of interest



    The author (Djo Hasan) declares that he has filed patent applications concerning P2X7R antagonists.

    Ethics approval and consent to participate



    Not applicable for this review article.

    Author contributions



    Conception, design and data handling: Djo Hasan
    Acquisition, analysis or interpretation of data for the manuscript: Djo Hasan
    Drafting and revising the manuscript: Djo Hasan
    Critically revising the manuscript for intellectual content: Djo Hasan
    Final approval of the version to be published: Djo Hasan
    Agreement to be accountable for all aspects of the work and ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: Djo Hasan.

    Funding



    None.

    Consent for publication



    I am the only author of this manuscript, and I have approved the manuscript for publication.

    Availability of data and materials



    Any dataset generated during and/or analyzed during the current study is available from the author upon reasonable request.

    [1] Miller FW (2023) The increasing prevalence of autoimmunity and autoimmune diseases: an urgent call to action for improved understanding, diagnosis, treatment, and prevention. Curr Opin Immunol 80: 102266. https://doi.org/10.1016/j.coi.2022.102266
    [2] Goldhaft TM, Wernicoff N (1948) High mortality associated with a widespread outbreak of Newcastle disease. Cornell Vet 38: 181-185.
    [3] Nelson CB, Pomeroy BS, Schrall K, et al. (1952) An outbreak of conjunctivitis due to Newcastle disease virus (NDV) occurring in poultry workers. Am J Public Health Nations Health 42: 672-678. https://doi.org/10.2105/AJPH.42.6.672
    [4] Trott DG, Pilsworth R (1965) Outbreaks of conjunctivitis due to the Newcastle disease virus among workers in chicken-broiler factories. Br Med J 2: 1514-1517. https://doi.org/10.1136/bmj.2.5477.1514
    [5] Rojas M, Restrepo-Jiménez P, Monsalve DM, et al. (2018) Molecular mimicry and autoimmunity. J Autoimmun 95: 100-123. https://doi.org/10.1016/j.jaut.2018.10.012
    [6] Suliman BA (2024) Potential clinical implications of molecular mimicry-induced autoimmunity. Immun Inflamm Dis 12: e1178. https://doi.org/10.1002/iid3.1178
    [7] Kanduc D, Shoenfeld Y (2020) Medical, genomic, and evolutionary aspects of the peptide Sharing between Pathogens, Primates, and Humans. Glob Med Genet 7: 64-67. https://doi.org/10.1055/s-0040-1716334
    [8] Oldstone MB (2014) Molecular mimicry: its evolution from concept to mechanism as a cause of autoimmune diseases. Monoclon Antib Immunodiagn Immunother 33: 158-165. https://doi.org/10.1089/mab.2013.0090
    [9] Santambrogio L, Marrack P (2023) The broad spectrum of pathogenic autoreactivity. Nat Rev Immunol 23: 69-70. https://doi.org/10.1038/s41577-022-00812-2
    [10] Simon CE (1909) On auto-antibody formation and antihemolysis. J Exp Med 11: 695-717. https://doi.org/10.1084/jem.11.5.695
    [11] Schwentker FF, Rivers TM (1934) The antibody response of rabbits to injections of emulsions and extracts of homologous brain. J Exp Med 60: 559-574. https://doi.org/10.1084/jem.60.5.559
    [12] Gear J (1945) Autoantigens and autoantibodies in the pathogenesis of disease with special refenence to blackwater fever. Trans R Soc Trop Med Hyg 39: 301-314. https://doi.org/10.1016/0035-9203(46)90041-7
    [13] Cavelti PA (1945) Autoantibodies in rheumatic fever. Proc Soc Exp Biol Med 60: 379-381. https://doi.org/10.3181/00379727-60-15197P
    [14] Liblau RS, Wong FS, Mars LT, et al. (2002) Autoreactive CD8 T cells in organ-specific autoimmunity: Emerging targets for therapeutic intervention. Immunity 17: 1-6. https://doi.org/10.1016/S1074-7613(02)00338-2
    [15] Shepard ER, Wegner A, Hill EV, et al. (2021) The mechanism of action of antigen processing independent T cell epitopes designed for immunotherapy of autoimmune diseases. Front Immunol 12: 654201. https://doi.org/10.3389/fimmu.2021.654201
    [16] Klein L, Robey EA, Hsieh CS (2019) Central CD4(+) T cell tolerance: deletion versus regulatory T cell differentiation. Nat Rev Immunol 19: 7-18. https://doi.org/10.1038/s41577-018-0083-6
    [17] Sharma C, Bayry J (2023) High risk of autoimmune diseases after COVID-19. Nat Rev Rheumatol 19: 399-400. https://doi.org/10.1038/s41584-023-00964-y
    [18] Lerner A, Benzvi C, Vojdani A (2023) Cross-reactivity and sequence similarity between microbial transglutaminase and human tissue antigens. Sci Rep 13: 17526. https://doi.org/10.1038/s41598-023-44452-5
    [19] Trier NH, Houen G (2023) Antibody cross-reactivity in auto-immune diseases. Int J Mol Sci 24. https://doi.org/10.3390/ijms241713609
    [20] English J, Patrick S, Stewart LD (2023) The potential role of molecular mimicry by the anaerobic microbiota in the aetiology of autoimmune disease. Anaerobe 80: 102721. https://doi.org/10.1016/j.anaerobe.2023.102721
    [21] Pisetsky DS (2023) Pathogenesis of autoimmune disease. Nat Rev Nephrol 19: 509-524. https://doi.org/10.1038/s41581-023-00720-1
    [22] Hasan D, Shono A, van Kalken CK, et al. (2022) A novel definition and treatment of hyperinflammation in COVID-19 based on purinergic signalling. Purinergic Signal 18: 13-59. https://doi.org/10.1007/s11302-021-09814-6
    [23] Jerne NK (1955) The natural-selection theory of antibody formation. Proc Natl Acad Sci USA 41: 849-857. https://doi.org/10.1073/pnas.41.11.849
    [24] Burnet FM (1976) A modification of Jerne's theory of antibody production using the concept of clonal selection. CA Cancer J Clin 26: 119-121. https://doi.org/10.3322/canjclin.26.2.119
    [25] Burnet FM (1957) A modification of Jerne's theory of antibody production using the concept of clonal selection. Aust J Sci 20: 67-69.
    [26] Rajendeeran A, Tenbrock K (2021) Regulatory T cell function in autoimmune disease. J Transl Autoimmun 4: 100130. https://doi.org/10.1016/j.jtauto.2021.100130
    [27] Dominguez-Villar M, Hafler DA (2018) Regulatory T cells in autoimmune disease. Nat Immunol 19: 665-673. https://doi.org/10.1038/s41590-018-0120-4
    [28] Santori FR, Arsov I, Lilić M, et al. (2002) Editing autoreactive TCR enables efficient positive selection. J Immunol 169: 1729-1734. https://doi.org/10.4049/jimmunol.169.4.1729
    [29] Zal T, Weiss S, Mellor A, et al. (1996) Expression of a second receptor rescues self-specific T cells from thymic deletion and allows activation of autoreactive effector function. Proc Natl Acad Sci USA 93: 9102-9107. https://doi.org/10.1073/pnas.93.17.9102
    [30] Ni PP, Solomon B, Hsieh CS, et al. (2014) The ability to rearrange dual TCRs enhances positive selection, leading to increased Allo- and Autoreactive T cell repertoires. J Immunol 193: 1778-1786. https://doi.org/10.4049/jimmunol.1400532
    [31] Auger JL, Haasken S, Steinert EM, et al. (2012) Incomplete TCR-β allelic exclusion accelerates spontaneous autoimmune arthritis in K/BxN TCR transgenic mice. Eur J Immunol 42: 2354-2362. https://doi.org/10.1002/eji.201242520
    [32] George TC, Bilsborough J, Viney JL, et al. (2003) High antigen dose and activated dendritic cells enable Th cells to escape regulatory T cell-mediated suppression in vitro. Eur J Immunol 33: 502-511. https://doi.org/10.1002/immu.200310026
    [33] Swee LK, Nusser A, Curti M, et al. (2014) The amount of self-antigen determines the effector function of murine T cells escaping negative selection. Eur J Immunol 44: 1299-1312.
    [34] Davis MM (2015) Not-so-negative selection. Immunity 43: 833-835. https://doi.org/10.1002/eji.201343840
    [35] Legoux FP, Lim JB, Cauley AW, et al. (2015) CD4+ T cell tolerance to tissue-restricted self antigens is mediated by antigen-specific regulatory T cells rather than deletion. Immunity 43: 896-908. https://doi.org/10.1016/j.immuni.2015.10.011
    [36] Rawlings DJ, Metzler G, Wray-Dutra M, et al. (2017) Altered B cell signalling in autoimmunity. Nat Rev Immunol 17: 421-436. https://doi.org/10.3390/cells10051190
    [37] Bonasia CG, Abdulahad WH, Rutgers A, et al. (2021) B cell activation and escape of tolerance checkpoints: Recent insights from studying autoreactive B cells. Cells 10: 1190. https://doi.org/10.3390/cells10051190
    [38] Giltiay NV, Chappell CP, Clark EA (2012) B-cell selection and the development of autoantibodies. Arthritis Res Ther 14. https://doi.org/10.1186/ar3918
    [39] Suurmond J, Diamond B (2015) Autoantibodies in systemic autoimmune diseases: specificity and pathogenicity. J Clin Invest 125: 2194-2202. https://doi.org/10.1172/JCI78084
    [40] Sakaguchi S, Wing K, Miyara M (2007) Regulatory T cells–a brief history and perspective. Eur J Immunol 37: S116-S123. https://doi.org/10.1002/eji.200737593
    [41] Wing JB, Tekgüç M, Sakaguchi S (2018) Control of germinal center responses by T-Follicular regulatory cells. Front Immunol 9: 1910. https://doi.org/10.3389/fimmu.2018.01910
    [42] Wing JB, Lim EL, Sakaguchi S (2020) Control of foreign Ag-specific Ab responses by Treg and Tfr. Immunol Rev 296: 104-119. https://doi.org/10.1111/imr.12888
    [43] Ding T, Su R, Wu R, et al. (2021) Frontiers of autoantibodies in autoimmune disorders: Crosstalk between Tfh/Tfr and regulatory B cells. Front Immunol 12: 641013. https://doi.org/10.3389/fimmu.2021.641013
    [44] Richards DM, Delacher M, Goldfarb Y, et al. (2015) Chapter eight-Treg cell differentiation: from thymus to peripheral tissue. Progress in Molecular Biology and Translational Science. New York: Academic Press 175-205. https://doi.org/10.1016/bs.pmbts.2015.07.014
    [45] Schmitt EG, Williams CB (2013) Generation and function of induced regulatory T cells. Front Immunol 4: 152. https://doi.org/10.3389/fimmu.2013.00152
    [46] Khantakova JN, Bulygin AS, Sennikov SV (2022) The regulatory-T-cell memory phenotype: What we know. Cells 11. https://doi.org/10.3390/cells11101687
    [47] Sanchez AM, Zhu J, Huang X, et al. (2012) The development and function of memory regulatory T cells after acute viral infections. J Immunol 189: 2805-2814. https://doi.org/10.4049/jimmunol.1200645
    [48] Rosenblum MD, Way SS, Abbas AK (2016) Regulatory T cell memory. Nat Rev Immunol 16: 90-101. https://doi.org/10.1038/nri.2015.1
    [49] Kaminski A, Hager FT, Kopplin L, et al. (2023) Resident regulatory T cells reflect the immune history of individual lymph nodes. Sci Immunol 8: eadj5789. https://doi.org/10.1126/sciimmunol.adj5789
    [50] Corthay A (2009) How do regulatory T cells work?. Scand J Immunol 70: 326-336. https://doi.org/10.1111/j.1365-3083.2009.02308.x
    [51] Sprouse ML, Scavuzzo MA, Blum S, et al. (2018) High self-reactivity drives T-bet and potentiates Treg function in tissue-specific autoimmunity. JCI Insight 3. https://doi.org/10.1172/jci.insight.97322
    [52] Zuany-Amorim C, Sawicka E, Manlius C, et al. (2002) Suppression of airway eosinophilia by killed Mycobacterium vaccae-induced allergen-specific regulatory T-cells. Nat Med 8: 625-629. https://doi.org/10.1038/nm0602-625
    [53] Belkaid Y, Piccirillo CA, Mendez S, et al. (2002) CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature 420: 502-507. https://doi.org/10.1038/nature01152
    [54] Suffia IJ, Reckling SK, Piccirillo CA, et al. (2006) Infected site-restricted Foxp3+ natural regulatory T cells are specific for microbial antigens. J Exp Med 203: 777-788. https://doi.org/10.1084/jem.20052056
    [55] Montagnoli C, Bacci A, Bozza S, et al. (2002) B7/CD28-dependent CD4+CD25+ regulatory T cells are essential components of the memory-protective immunity to Candida albicans. J Immunol 169: 6298-6308. https://doi.org/10.4049/jimmunol.169.11.6298
    [56] McGuirk P, McCann C, Mills KH (2002) Pathogen-specific T regulatory 1 cells induced in the respiratory tract by a bacterial molecule that stimulates interleukin 10 production by dendritic cells: a novel strategy for evasion of protective T helper type 1 responses by Bordetella pertussis. J Exp Med 195: 221-231. https://doi.org/10.1084/jem.20011288
    [57] Kullberg MC, Jankovic D, Gorelick PL, et al. (2002) Bacteria-triggered CD4(+) T regulatory cells suppress Helicobacter hepaticus-induced colitis. J Exp Med 196: 505-515. https://doi.org/10.1084/jem.20020556
    [58] Ochando JC, Yopp AC, Yang Y, et al. (2005) Lymph node occupancy is required for the peripheral development of alloantigen-specific Foxp3+ regulatory T cells. J Immunol 174: 6993-7005. https://doi.org/10.4049/jimmunol.174.11.6993
    [59] van Maurik A, Herber M, Wood KJ, et al. (2002) Cutting edge: CD4+CD25+ alloantigen-specific immunoregulatory cells that can prevent CD8+ T cell-mediated graft rejection: implications for anti-CD154 immunotherapy. J Immunol 169: 5401-5404. https://doi.org/10.4049/jimmunol.169.10.5401
    [60] Smith DG, Martinelli R, Besra GS, et al. (2019) Identification and characterization of a novel anti-inflammatory lipid isolated from Mycobacterium vaccae, a soil-derived bacterium with immunoregulatory and stress resilience properties. Psychopharmacology 236: 1653-1670. https://doi.org/10.1007/s00213-019-05253-9
    [61] Múnera M, Farak J, Pérez M, et al. (2020) Prediction of molecular mimicry between antigens from Leishmania sp. and human: Implications for autoimmune response in systemic lupus erythematosus. Microb Pathog 148: 104444. https://doi.org/10.1016/j.micpath.2020.104444
    [62] Argov S, Jaffe CL, Krupp M, et al. (1989) Autoantibody production by patients infected with Leishmania. Clin Exp Immunol 76: 190-197.
    [63] Gustafson KS, Vercellotti GM, Bendel CM, et al. (1991) Molecular mimicry in Candida albicans. Role of an integrin analogue in adhesion of the yeast to human endothelium. J Clin Invest 87: 1896-1902. https://doi.org/10.1172/JCI115214
    [64] Vojdani A, Rahimian P, Kalhor H, et al. (1996) Immunological cross reactivity between Candida albicans and human tissue. J Clin Lab Immunol 48: 1-15.
    [65] Sandros J, Rozdzinski E, Zheng J, et al. (1994) Lectin domains in the toxin of Bordetella pertussis: selectin mimicry linked to microbial pathogenesis. Glycoconj J 11: 501-506. https://doi.org/10.1007/BF00731300
    [66] Sandros J, Tuomanen E (1993) Attachment factors of Bordetella pertussis: mimicry of eukaryotic cell recognition molecules. Trends Microbiol 1: 192-196. https://doi.org/10.1016/0966-842X(93)90090-E
    [67] Alyamani EJ, Brandt P, Pena JA, et al. (2007) Helicobacter hepaticus catalase shares surface-predicted epitopes with mammalian catalases. Microbiology (Reading) 153: 1006-1016. https://doi.org/10.1099/mic.0.29184-0
    [68] Macdonald WA, Chen Z, Gras S, et al. (2009) T cell allorecognition via molecular mimicry. Immunity 31: 897-908. https://doi.org/10.1016/j.immuni.2009.09.025
    [69] Koyama M, Hill GR (2016) Alloantigen presentation and graft-versus-host disease: fuel for the fire. Blood 127: 2963-2970. https://doi.org/10.1182/blood-2016-02-697250
    [70] Hudson KE, Wong ASL, Richards AL, et al. (2019) Alloimmunogenicity of an isolated MHC allele is affected by the context of MHC mismatch in a murine model. Transfusion 59: 744-753. https://doi.org/10.1111/trf.15109
    [71] Mondino S, Schmidt S, Buchrieser C (2020) Molecular mimicry: A paradigm of host-microbe coevolution illustrated by legionella. mBio 11. https://doi.org/10.1128/mBio.01201-20
    [72] Pacholczyk R, Kern J, Singh N, et al. (2007) Nonself-antigens are the cognate specificities of Foxp3+ regulatory T cells. Immunity 27: 493-504. https://doi.org/10.1016/j.immuni.2007.07.019
    [73] Stephens GL, Shevach EM (2007) Foxp3+ regulatory T cells: selfishness under scrutiny. Immunity 27: 417-419.
    [74] Vignali DA, Collison LW, Workman CJ (2008) How regulatory T cells work. NatRev Immunol 8: 523-532. https://doi.org/10.1038/nri2343
    [75] Tan D, Yin W, Guan F, et al. (2022) B cell-T cell interplay in immune regulation: A focus on follicular regulatory T and regulatory B cell functions. Front Cell Dev Biol 10: 991840. https://doi.org/10.3389/fcell.2022.991840
    [76] Rosser EC, Mauri C (2015) Regulatory B cells: origin, phenotype, and function. Immunity 42: 607-612. https://doi.org/10.1016/j.immuni.2015.04.005
    [77] Wang R, Xie R, Song Z (2018) Circulating regulatory Tfh cells are enriched in patients with chronic hepatitis B infection and induce the differentiation of regulatory B cells. Exp Cell Res 365: 171-176. https://doi.org/10.1016/j.yexcr.2018.02.031
    [78] Li H, Zhou R, Wang C, et al. (2018) T follicular regulatory cells infiltrate the human airways during the onset of acute respiratory distress syndrome and regulate the development of B regulatory cells. Immunol Res 66: 548-554. https://doi.org/10.1007/s12026-018-9014-7
    [79] Catalán D, Mansilla MA, Ferrier A, et al. (2021) Immunosuppressive mechanisms of regulatory B Cells. Front Immunol 12. https://doi.org/10.3389/fimmu.2021.611795
    [80] Figueiró F, Muller L, Funk S, et al. (2016) Phenotypic and functional characteristics of CD39 (high) human regulatory B cells (Breg). Oncoimmunology 5: e1082703. https://doi.org/10.1080/2162402X.2015.1082703
    [81] Kaku H, Cheng KF, Al-Abed Y, et al. (2014) A novel mechanism of B cell-mediated immune suppression through CD73 expression and adenosine production. J Immunol 193: 5904-5913. https://doi.org/10.4049/jimmunol.1400336
    [82] Saze Z, Schuler PJ, Hong CS, et al. (2013) Adenosine production by human B cells and B cell-mediated suppression of activated T cells. Blood 122: 9-18. https://doi.org/10.1182/blood-2013-02-482406
    [83] Khan AR, Hams E, Floudas A, et al. (2015) PD-L1hi B cells are critical regulators of humoral immunity. Nat Commun 6: 5997. https://doi.org/10.1038/ncomms6997
    [84] Wang K, Tao L, Su J, et al. (2017) TLR4 supports the expansion of FasL(+)CD5(+)CD1d(hi) regulatory B cells, which decreases in contact hypersensitivity. Mol Immunol 87: 188-199. https://doi.org/10.1016/j.molimm.2017.04.016
    [85] Ma L, Liu B, Jiang Z, et al. (2014) Reduced numbers of regulatory B cells are negatively correlated with disease activity in patients with new-onset rheumatoid arthritis. Clin Rheumatol 33: 187-195. https://doi.org/10.1007/s10067-013-2359-3
    [86] Yang M, Deng J, Liu Y, et al. (2012) IL-10-producing regulatory B10 cells ameliorate collagen-induced arthritis via suppressing Th17 cell generation. Am J Pathol 180: 2375-2385. https://doi.org/10.1016/j.ajpath.2012.03.010
    [87] Flores-Borja F, Bosma A, Ng D, et al. (2013) CD19+CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation. Sci Transl Med 5: 173ra123. https://doi.org/10.1126/scitranslmed.3005407
    [88] Carter NA, Rosser EC, Mauri C (2012) Interleukin-10 produced by B cells is crucial for the suppression of Th17/Th1 responses, induction of T regulatory type 1 cells and reduction of collagen-induced arthritis. Arthritis Res Ther 14: R32. https://doi.org/10.1186/ar3736
    [89] Gondek DC, Lu LF, Quezada SA, et al. (2005) Cutting edge: contact-mediated suppression by CD4+CD25+ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. J Immunol 174: 1783-1786. https://doi.org/10.4049/jimmunol.174.4.1783
    [90] Jahrsdörfer B, Vollmer A, Blackwell SE, et al. (2010) Granzyme B produced by human plasmacytoid dendritic cells suppresses T-cell expansion. Blood 115: 1156-1165. https://doi.org/10.1182/blood-2009-07-235382
    [91] Xu L, Liu X, Liu H, et al. (2017) Impairment of granzyme B-producing regulatory B cells correlates with exacerbated rheumatoid arthritis. Front Immunol 8: 768. https://doi.org/10.3389/fimmu.2017.00768
    [92] Saraiva M, Vieira P, O'Garra A (2019) Biology and therapeutic potential of interleukin-10. J Exp Med 217. https://doi.org/10.1084/jem.20190418
    [93] Zysk W, Gleń J, Trzeciak M (2022) Current insight into the role of IL-35 and its potential involvement in the pathogenesis and therapy of atopic dermatitis. Int J Mol Sci 23: 15709. https://doi.org/10.3390/ijms232415709
    [94] Massagué J, Sheppard D (2023) TGF-β signaling in health and disease. Cell 186: 4007-4037. https://doi.org/10.1016/j.cell.2023.07.036
    [95] Needham EJ, Stoevesandt O, Thelin EP, et al. (2021) Complex autoantibody responses occur following moderate to severe traumatic brain injury. J Immunol 207: 90-100. https://doi.org/10.4049/jimmunol.2001309
    [96] Zhang Z, Zoltewicz JS, Mondello S, et al. (2014) Human traumatic brain injury induces autoantibody response against glial fibrillary acidic protein and its breakdown products. PLoS One 9: e92698. https://doi.org/10.1371/journal.pone.0092698
    [97] Zimering MB (2023) Repeated traumatic brain injury is associated with neurotoxic plasma autoantibodies directed against the serotonin 2A and alpha 1 adrenergic receptors. Endocrinol Diabetes Metab J 7: 1-12. https://doi.org/10.31038/EDMJ.2023722
    [98] Zimering MB, Pulikeyil AT, Myers CE, et al. (2020) Serotonin 2A receptor autoantibodies increase in adult traumatic brain injury in association with neurodegeneration. J Endocrinol Diabetes 7: 1-8. https://doi.org/10.15226/2374-6890/7/1/001142
    [99] Vijapur SM, Yang Z, Barton DJ, et al. (2020) Anti-pituitary and anti-hypothalamus autoantibody associations with inflammation and persistent hypogonadotropic hypogonadism in men with traumatic brain injury. J Neurotrauma 37: 1609-1626. https://doi.org/10.1089/neu.2019.6780
    [100] Arevalo-Martin A, Grassner L, Garcia-Ovejero D, et al. (2018) Elevated autoantibodies in subacute human spinal cord injury are naturally occurring antibodies. Front Immunol 9. https://doi.org/10.3389/fimmu.2018.02365
    [101] Schwab JM, Haider C, Kopp MA, et al. (2023) Lesional antibody synthesis and complement deposition associate with de novo antineuronal antibody synthesis after spinal cord injury. Neurol Neuroimmunol Neuroinflammation 10: e200099. https://doi.org/10.1212/NXI.0000000000200099
    [102] Caputo F, Barranco R, Ricci P, et al. (2021) An unusual case of coma related to glutamate receptor 3 (GluR3) auto-antibodies after a traumatic spinal cord injury: Clinical and pathological aspects. Med Leg J 89: 133-136. https://doi.org/10.1177/0025817220970069
    [103] Davies AL, Hayes KC, Dekaban GA (2007) Clinical correlates of elevated serum concentrations of cytokines and autoantibodies in patients with spinal cord injury. Arch Phys Med Rehabil 88: 1384-1393. https://doi.org/10.1016/j.apmr.2007.08.004
    [104] Hayes KC, Hull TC, Delaney GA, et al. (2002) Elevated serum titers of proinflammatory cytokines and CNS autoantibodies in patients with chronic spinal cord injury. J Neurotrauma 19: 753-761. https://doi.org/10.1089/08977150260139129
    [105] Panoutsakopoulou V, Sanchirico ME, Huster KM, et al. (2001) Analysis of the relationship between viral infection and autoimmune disease. Immunity 15: 137-147. https://doi.org/10.1016/S1074-7613(01)00172-8
    [106] Wang EY, Mao T, Klein J, et al. (2021) Diverse functional autoantibodies in patients with COVID-19. Nature 595: 283-288. https://doi.org/10.1038/s41586-021-03631-y
    [107] Trahtemberg U, Rottapel R, Dos Santos CC, et al. (2021) Anticardiolipin and other antiphospholipid antibodies in critically ill COVID-19 positive and negative patients. Ann Rheum Dis 80: 1236-1240. https://doi.org/10.1136/annrheumdis-2021-220206
    [108] Chang SE, Feng A, Meng W, et al. (2021) New-onset IgG autoantibodies in hospitalized patients with COVID-19. Nat Commun 12: 5417. https://doi.org/10.1038/s41467-021-25509-3
    [109] Arthur JM, Forrest JC, Boehme KW, et al. (2021) Development of ACE2 autoantibodies after SARS-CoV-2 infection. PLoS One 16: e0257016. https://doi.org/10.1371/journal.pone.0257016
    [110] Humphrey JH (1948) The pathogenesis of glomerulonephritis; a reinvestigation of the auto-immunization hypothesis. J Pathol Bacteriol 60: 211-218. https://doi.org/10.1002/path.1700600208
    [111] Cavelti PA (1947) Studies on the pathogenesis of rheumatic fever; experimental production of autoantibodies to heart, skeletal muscle and connective tissue. Arch Pathol (Chic) 44: 1-12.
    [112] Cavelti PA (1947) Studies on the pathogenesis of rheumatic fever; cardiac lesions produced in rats by means of autoantibodies to heart and connective tissues. Arch Pathol (Chic) 44: 13-27.
    [113] Cavelti PA (1947) Pathogenesis of glomerulonephritis and rheumatic fever; in vivo activation of tissue antigens as a result of streptococcic infection and consecutive formation of autoantibodies. Arch Pathol (Chic) 44: 119-125.
    [114] Segal Y, Shoenfeld Y (2018) Vaccine-induced autoimmunity: the role of molecular mimicry and immune crossreaction. Cell Mol Immunol 15: 586-594. https://doi.org/10.1038/cmi.2017.151
    [115] Talotta R (2023) Molecular mimicry and HLA polymorphisms may drive autoimmunity in recipients of the BNT-162b2 mRNA vaccine: A computational analysis. Microorganisms 11. https://doi.org/10.3390/microorganisms11071686
    [116] Franco A, Song J, Chambers C, et al. (2023) SARS-CoV-2 spike-specific regulatory T cells (Treg) expand and develop memory in vaccine recipients suggesting a role for immune regulation in preventing severe symptoms in COVID-19. Autoimmunity 56: 2259133. https://doi.org/10.1080/08916934.2023.2259133
    [117] Fiorelli D, Caruso V, Belardi R, et al. (2023) Evaluation of autoantibody profile in healthy subjects after mRNA vaccination against COVID-19. Int Immunopharmacol 122: 110592. https://doi.org/10.1016/j.intimp.2023.110592
    [118] Greinacher A, Selleng K, Palankar R, et al. (2021) Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia. Blood 138: 2256-2268. https://doi.org/10.1182/blood.2021013231
    [119] Greinacher A, Thiele T, Warkentin TE, et al. (2021) Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med 384: 2092-2101. https://doi.org/10.1056/NEJMoa2104840
    [120] Krashias G, Pafiti A, Deeba E, et al. (2022) SARS CoV-2 vaccination induces antibodies against cardiolipin. BMC Res Notes 15: 292. https://doi.org/10.1186/s13104-022-06180-3
    [121] Xu W, Wen X, Cong X, et al. (2023) COVID-19 mRNA vaccine, but not a viral vector-based vaccine, promotes neutralizing anti-type I interferon autoantibody production in a small group of healthy individuals. J Med Virol 95: e29137. https://doi.org/10.1002/jmv.29137
    [122] Aladdin Y, Algahtani H, Shirah B (2021) Vaccine-induced immune thrombotic thrombocytopenia with disseminated intravascular coagulation and death following the ChAdOx1 nCoV-19 vaccine. J Stroke Cerebrovasc Dis 30: 105938. https://doi.org/10.1016/j.jstrokecerebrovasdis.2021.105938
    [123] Alami A, Villeneuve PJ, Farrell PJ, et al. (2023) Myocarditis and pericarditis post-mRNA COVID-19 vaccination: Insights from a pharmacovigilance perspective. J Clin Med 12. https://doi.org/10.3390/jcm12154971
    [124] Di Dedda EA, Barison A, Aquaro GD, et al. (2022) Cardiac magnetic resonance imaging of myocarditis and pericarditis following COVID-19 vaccination: a multicenter collection of 27 cases. Eur Radiol : 1-9. https://doi.org/10.1007/s00330-022-08566-0
    [125] Yap J, Tham MY, Poh J, et al. (2022) Pericarditis and myocarditis after COVID-19 mRNA vaccination in a nationwide setting. Ann Acad Med Singap 51: 96-100. https://doi.org/10.47102/annals-acadmedsg.2021425
    [126] Galván-Peña S, Leon J, Chowdhary K, et al. (2021) Profound Treg perturbations correlate with COVID-19 severity. Proc Natl Acad Sci USA 118. https://doi.org/10.1073/pnas.2111315118
    [127] Neumann J, Prezzemolo T, Vanderbeke L, et al. (2020) Increased IL-10-producing regulatory T cells are characteristic of severe cases of COVID-19. Clin Transl Immunol 9: e1204. https://doi.org/10.1002/cti2.1204
    [128] Vick SC, Frutoso M, Mair F, et al. (2021) A regulatory T cell signature distinguishes the immune landscape of COVID-19 patients from those with other respiratory infections. Sci Adv 7: eabj0274. https://doi.org/10.1126/sciadv.abj0274
    [129] Saheb Sharif-Askari F, Saheb Sharif-Askari N, Hafezi S, et al. (2023) Increased blood immune regulatory cells in severe COVID-19 with autoantibodies to type I interferons. Sci Rep 13: 17344. https://doi.org/10.1038/s41598-023-43675-w
    [130] Wang F, Hou H, Luo Y, et al. (2020) The laboratory tests and host immunity of COVID-19 patients with different severity of illness. JCI Insight 5. https://doi.org/10.1172/jci.insight.137799
    [131] Sadeghi A, Tahmasebi S, Mahmood A, et al. (2020) Th17 and Treg cells function in SARS-CoV2 patients compared with healthy controls. J Cell Physiol 4: 2829-2839. https://doi.org/10.1002/jcp.30047
    [132] Chen G, Wu D, Guo W, et al. (2020) Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest 130: 2620-2629. https://doi.org/10.1172/JCI137244
    [133] Mohebbi SR, Baghaei K, Rostami-Nejad M, et al. (2020) Significant changes of CD4, FOXP3, CD25, and IL6 expression level in Iranian COVID-19 patients. Gastroenterol Hepatol Bed Bench 13: 388-392.
    [134] Caldrer S, Mazzi C, Bernardi M, et al. (2021) Regulatory T cells as predictors of clinical course in hospitalised COVID-19 patients. Front Immunol 12: 789735. https://doi.org/10.3389/fimmu.2021.789735
    [135] Meckiff BJ, Ramírez-Suástegui C, Fajardo V, et al. (2020) Imbalance of regulatory and cytotoxic SARS-CoV-2-Reactive CD4(+) T Cells in COVID-19. Cell 183: 1340-1353.e16. https://doi.org/10.3410/f.738790055.793579433
    [136] Rojas M, Herrán M, Ramírez-Santana C, et al. (2023) Molecular mimicry and autoimmunity in the time of COVID-19. J Autoimmun 139: 103070. https://doi.org/10.1016/j.jaut.2023.103070
    [137] Gouttefangeas C, Klein R, Maia A (2023) The good and the bad of T cell cross-reactivity: challenges and opportunities for novel therapeutics in autoimmunity and cancer. Front Immunol 14. https://doi.org/10.3389/fimmu.2023.1212546
    [138] Grassi F, Salina G (2023) The P2X7 receptor in autoimmunity. Int J Mol Sci 24: 14116. https://doi.org/10.3390/ijms241814116
    [139] Di Virgilio F, Giuliani AL (2016) Purinergic signalling in autoimmunity: A role for the P2X7R in systemic lupus erythematosus?. Biomed J 39: 326-338. https://doi.org/10.1016/j.bj.2016.08.006
    [140] Drury AN, Szent-Gyorgyi A (1929) The physiological activity of adenine compounds with especial reference to their action upon the mammalian heart. J Physiol 68: 213-237. https://doi.org/10.1113/jphysiol.1929.sp002608
    [141] Lohmann K (1929) Über die Pyrophosphatfraktion im Muskel. Naturwissenschaften 17: 624-625. https://doi.org/10.1007/BF01506215
    [142] Engelhardt WA, Ljubimowa MN (1939) Myosine and Adenosinetriphosphatase. Nature 144: 668-669. https://doi.org/10.1038/144668b0
    [143] Lipmann F (1940) A phosphorylated oxygenation product of pyruvic acid. J Biol Chem 134: 463-464. https://doi.org/10.1016/S0021-9258(18)73290-0
    [144] Lipmann F (1944) Enzymatic synthesis of acetyl phosphate. J Biol Chem 155: 55-70. https://doi.org/10.1016/S0021-9258(18)43172-9
    [145] Lipmann F, Jones ME, Black S, et al. (1953) The mechanism of the ATP-CoA-acetate reaction. J Cell Physiol Suppl 41: 109-112. https://doi.org/10.1002/jcp.1030410408
    [146] Feldberg W, Hebb C (1948) The stimulating action of phosphate compounds on the perfused superior cervical ganglion of the cat. J Physiol 107: 210-221. https://doi.org/10.1113/jphysiol.1948.sp004264
    [147] Holton P (1959) The liberation of adenosine triphosphate on antidromic stimulation of sensory nerves. J Physiol 145: 494-504. https://doi.org/10.1113/jphysiol.1959.sp006157
    [148] Burnstock G (1972) Purinergic nerves. Pharmacol Rev 24: 509-581.
    [149] Burnstock G (2012) Purinergic signalling: Its unpopular beginning, its acceptance and its exciting future. Bioessays 34: 218-225. https://doi.org/10.1002/bies.201100130
    [150] Burnstock G (2014) Purinergic signalling: from discovery to current developments. Exp Physiol 99: 16-34. https://doi.org/10.1113/expphysiol.2013.071951
    [151] Surprenant A, Rassendren F, Kawashima E, et al. (1996) The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X7). Science 272: 735-738. https://doi.org/10.1126/science.272.5262.735
    [152] Di Virgilio F (1995) The P2Z purinoceptor: an intriguing role in immunity, inflammation and cell death. Immunol Today 16: 524-528. https://doi.org/10.1016/0167-5699(95)80045-X
    [153] Ai Y, Wang H, Liu L, et al. (2023) Purine and purinergic receptors in health and disease. MedComm 4: e359. https://doi.org/10.1002/mco2.359
    [154] Burnstock G (2020) Introduction to purinergic signaling. Methods Mol Biol 2041: 1-15. https://doi.org/10.1007/978-1-4939-9717-6_1
    [155] Ralevic V, Burnstock G (1998) Receptors for purines and pyrimidines. Pharmacol Rev 50: 413-492.
    [156] Burnstock G (2018) Purine and purinergic receptors. Brain Neurosci Adv 2. https://doi.org/10.1177/2398212818817494
    [157] Fredholm BB, Frenguelli BG, Hills R, et al. (2023) Adenosine receptors in GtoPdb v.2023.1. IUPHAR/BPS Guide to Pharmacology CITE 2023. https://doi.org/10.2218/gtopdb/F3/2023.1
    [158] Di Virgilio F, Falzoni S, Fortuny-Gomez A, et al. (2023) P2X receptors in GtoPdb v.2023.1. IUPHAR/BPS Guide to Pharmacology CITE . https://doi.org/10.2218/gtopdb/F77/2023.1
    [159] Abbracchio M-P, Boeynaems J-M, Boyer JL, et al. (2023) P2Y receptors in GtoPdb v.2023.1. IUPHAR/BPS Guide to Pharmacology CITE 1. https://doi.org/10.2218/gtopdb/F52/2023.1
    [160] Cotrina ML, Nedergaard M (2009) Physiological and pathological functions of P2X7 receptor in the spinal cord. Purinergic Signal 5: 223-232. https://doi.org/10.1007/s11302-009-9138-2
    [161] Alves LA, Bezerra RJ, Faria RX, et al. (2013) Physiological roles and potential therapeutic applications of the P2X7 receptor in inflammation and pain. Molecules 18: 10953-10972. https://doi.org/10.3390/molecules180910953
    [162] Hasan D, Blankman P, Nieman GF (2017) Purinergic signalling links mechanical breath profile and alveolar mechanics with the pro-inflammatory innate immune response causing ventilation-induced lung injury. Purinergic Signal 13: 363-386. https://doi.org/10.1007/s11302-017-9564-5
    [163] Hasan D, Satalin J, van der Zee P, et al. (2018) Excessive extracellular ATP desensitizes P2Y2 and P2X4 ATP receptors provoking surfactant impairment ending in ventilation-induced lung injury. Int J Mol Sci 19: 1185. https://doi.org/10.3390/ijms19041185
    [164] Patel AS, Reigada D, Mitchell CH, et al. (2005) Paracrine stimulation of surfactant secretion by extracellular ATP in response to mechanical deformation. Am J Physiol Lung Cell MolPhysiol 289: L489-L496. https://doi.org/10.1152/ajplung.00074.2005
    [165] Kim KC, Zheng QX, Van-Seuningen I (1993) Involvement of a signal transduction mechanism in ATP-induced mucin release from cultured airway goblet cells. Am J Respir Cell Mol Biol 8: 121-125. https://doi.org/10.1165/ajrcmb/8.2.121
    [166] Tozzi M, Larsen AT, Lange SC, et al. (2018) The P2X7 receptor and pannexin-1 are involved in glucose-induced autocrine regulation in beta-cells. Sci Rep 8: 8926. https://doi.org/10.1038/s41598-018-27281-9
    [167] Jacques-Silva MC, Correa-Medina M, Cabrera O, et al. (2010) ATP-gated P2X3 receptors constitute a positive autocrine signal for insulin release in the human pancreatic beta cell. Proc Natl Acad Sci USA 107: 6465-6470. https://doi.org/10.1073/pnas.0908935107
    [168] Eltzschig HK, Sitkovsky MV, Robson SC (2012) Purinergic signaling during inflammation. N Engl J Med 367: 2322-2333. https://doi.org/10.1056/NEJMra1205750
    [169] Idzko M, Ferrari D, Eltzschig HK (2014) Nucleotide signalling during inflammation. Nature 509: 310-317. https://doi.org/10.1038/nature13085
    [170] Cekic C, Linden J (2016) Purinergic regulation of the immune system. Nat Rev Immunol 16: 177-192. https://doi.org/10.1038/nri.2016.4
    [171] Adinolfi E, Giuliani AL, De Marchi E, et al. (2018) The P2X7 receptor: A main player in inflammation. Biochem Pharmacol 151: 234-244. https://doi.org/10.1016/j.bcp.2017.12.021
    [172] Savio LEB, de Andrade Mello P, da Silva CG, et al. (2018) The P2X7 receptor in inflammatory diseases: Angel or demon?. Front Pharmacol 9: 52. https://doi.org/10.3389/fphar.2018.00052
    [173] Zarek PE, Huang CT, Lutz ER, et al. (2008) A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood 111: 251-259. https://doi.org/10.1182/blood-2007-03-081646
    [174] Ohta A, Kini R, Ohta A, et al. (2012) The development and immunosuppressive functions of CD4(+) CD25(+) FoxP3(+) regulatory T cells are under influence of the adenosine-A2A adenosine receptor pathway. Front Immunol 3: 190. https://doi.org/10.3389/fimmu.2012.00190
    [175] Shi L, Feng M, Du S, et al. (2019) Adenosine generated by regulatory T cells induces CD8(+) T cell exhaustion in gastric cancer through A2aR pathway. Biomed Res Int 2019: 4093214. https://doi.org/10.1155/2019/4093214
    [176] Wiley JS, Gu BJ (2012) A new role for the P2X7 receptor: a scavenger receptor for bacteria and apoptotic cells in the absence of serum and extracellular ATP. Purinergic Signal 8: 579-586. https://doi.org/10.1007/s11302-012-9308-5
    [177] Gu BJ, Saunders BM, Petrou S, et al. (2011) P2X(7) is a scavenger receptor for apoptotic cells in the absence of its ligand, extracellular ATP. J Immunol 187: 2365-2375. https://doi.org/10.4049/jimmunol.1101178
    [178] Brandao-Burch A, Key ML, Patel JJ, et al. (2012) The P2X7 receptor is an important regulator of extracellular ATP levels. Front Endocrinol (Lausanne) 3: 41. https://doi.org/10.3389/fendo.2012.00041
    [179] Gutierrez-Martin Y, Bustillo D, Gomez-Villafuertes R, et al. (2011) P2X7 receptors trigger ATP exocytosis and modify secretory vesicle dynamics in neuroblastoma cells. J Biol Chem 286: 11370-11381. https://doi.org/10.1074/jbc.M110.139410
    [180] Suadicani SO, Brosnan CF, Scemes E (2006) P2X7 receptors mediate ATP release and amplification of astrocytic intercellular Ca2+ signaling. J Neurosci 26: 1378-1385. https://doi.org/10.1523/JNEUROSCI.3902-05.2006
    [181] Henriquez M, Herrera-Molina R, Valdivia A, et al. (2011) ATP release due to Thy-1-integrin binding induces P2X7-mediated calcium entry required for focal adhesion formation. J Cell Sci 124: 1581-1588. https://doi.org/10.1242/jcs.073171
    [182] Mishra A, Chintagari NR, Guo Y, et al. (2011) Purinergic P2X7 receptor regulates lung surfactant secretion in a paracrine manner. J Cell Sci 124: 657-668. https://doi.org/10.1242/jcs.066977
    [183] Ohshima Y, Tsukimoto M, Takenouchi T, et al. (2010) gamma-Irradiation induces P2X(7) receptor-dependent ATP release from B16 melanoma cells. Biochim Biophys Acta 1800: 40-46.
    [184] Johnsen B, Kaschubowski KE, Nader S, et al. (2019) P2X7A-mediated ATP secretion is accompanied by depletion of cytosolic ATP. Purinergic Signal 15: 155-166. https://doi.org/10.1007/s11302-019-09654-5
    [185] Sáez PJ, Vargas P, Shoji KF, et al. (2017) ATP promotes the fast migration of dendritic cells through the activity of pannexin 1 channels and P2X(7) receptors. Sci Signal 10. https://doi.org/10.1126/scisignal.aah7107
    [186] Basu M, Gupta P, Dutta A, et al. (2020) Increased host ATP efflux and its conversion to extracellular adenosine is crucial for establishing Leishmania infection. J Cell Sci 133. https://doi.org/10.1242/jcs.239939
    [187] Atkinson SK, Morice AH, Sadofsky LR (2020) Rhinovirus-16 increases ATP release in A549 cells without concomitant increase in production. ERJ Open Res 6. https://doi.org/10.1183/23120541.00159-2020
    [188] Ledderose C, Valsami EA, Elevado M, et al. (2023) ATP release from influenza-infected lungs enhances neutrophil activation and promotes disease progression. J Infect Dis . https://doi.org/10.1093/infdis/jiad442
    [189] Zhang C, He H, Wang L, et al. (2017) Virus-triggered ATP release limits viral replication through facilitating IFN-β production in a P2X7-dependent manner. J Immunol 199: 1372-1381. https://doi.org/10.4049/jimmunol.1700187
    [190] Adinolfi E, Callegari MG, Ferrari D, et al. (2005) Basal activation of the P2X7 ATP receptor elevates mitochondrial calcium and potential, increases cellular ATP levels, and promotes serum-independent growth. Mol Biol Cell 16: 3260-3272. https://doi.org/10.1091/mbc.e04-11-1025
    [191] Ghazi K, Deng-Pichon U, Warnet JM, et al. (2012) Hyaluronan fragments improve wound healing on in vitro cutaneous model through P2X7 purinoreceptor basal activation: role of molecular weight. PLoS One 7: e48351. https://doi.org/10.1371/journal.pone.0048351
    [192] Adinolfi E, Callegari MG, Cirillo M, et al. (2009) Expression of the P2X7 receptor increases the Ca2+ content of the endoplasmic reticulum, activates NFATc1, and protects from apoptosis. J Biol Chem 284: 10120-10128. https://doi.org/10.1074/jbc.M805805200
    [193] Gilbert SM, Oliphant CJ, Hassan S, et al. (2019) ATP in the tumour microenvironment drives expression of nfP2X7, a key mediator of cancer cell survival. Oncogene 38: 194-208. https://doi.org/10.1038/s41388-018-0426-6
    [194] Pellegatti P, Falzoni S, Donvito G, et al. (2011) P2X7 receptor drives osteoclast fusion by increasing the extracellular adenosine concentration. Faseb j 25: 1264-1274. https://doi.org/10.1096/fj.10-169854
    [195] Amoroso F, Falzoni S, Adinolfi E, et al. (2012) The P2X7 receptor is a key modulator of aerobic glycolysis. Cell Death Dis 3: e370. https://doi.org/10.1038/cddis.2012.105
    [196] Schenk U, Frascoli M, Proietti M, et al. (2011) ATP inhibits the generation and function of regulatory T cells through the activation of purinergic P2X receptors. Sci Signal 4: ra12. https://doi.org/10.1126/scisignal.2001270
    [197] Figliuolo VR, Savio LEB, Safya H, et al. (2017) P2X7 receptor promotes intestinal inflammation in chemically induced colitis and triggers death of mucosal regulatory T cells. Biochim Biophys Acta Mol Basis Dis 1863: 1183-1194. https://doi.org/10.1016/j.bbadis.2017.03.004
    [198] Koo TY, Lee JG, Yan JJ, et al. (2017) The P2X7 receptor antagonist, oxidized adenosine triphosphate, ameliorates renal ischemia-reperfusion injury by expansion of regulatory T cells. Kidney Int 92: 415-431. https://doi.org/10.1016/j.kint.2017.01.031
    [199] Hubert S, Rissiek B, Klages K, et al. (2010) Extracellular NAD+ shapes the Foxp3+ regulatory T cell compartment through the ART2-P2X7 pathway. J Exp Med 207: 2561-2568. https://doi.org/10.1084/jem.20091154
    [200] Wilhelm K, Ganesan J, Muller T, et al. (2010) Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R. Nat Med 16: 1434-1438. https://doi.org/10.1038/nm.2242
    [201] Elhage A, Cuthbertson P, Sligar C, et al. (2023) A species-specific anti-human P2X7 monoclonal antibody reduces Graft-versus-Host disease in humanised mice. Pharmaceutics 15. https://doi.org/10.3390/pharmaceutics15092263
    [202] Raffaghello L, Principi E, Baratto S, et al. (2022) P2X7 receptor antagonist reduces fibrosis and inflammation in a mouse model of alpha-sarcoglycan muscular dystrophy. Pharmaceuticals (Basel) 15. https://doi.org/10.3390/ph15010089
    [203] Pupovac A, Foster CM, Sluyter R (2013) Human P2X7 receptor activation induces the rapid shedding of CXCL16. Biochem Biophys Res Commun 432: 626-631. https://doi.org/10.1016/j.bbrc.2013.01.134
    [204] Pupovac A, Geraghty NJ, Watson D, et al. (2015) Activation of the P2X7 receptor induces the rapid shedding of CD23 from human and murine B cells. Immunol Cell Biol 93: 77-85. https://doi.org/10.1038/icb.2014.69
    [205] Yip L, Woehrle T, Corriden R, et al. (2009) Autocrine regulation of T-cell activation by ATP release and P2X7 receptors. FASEB J 23: 1685-1693. https://doi.org/10.1096/fj.08-126458
    [206] Huang SW, Walker C, Pennock J, et al. (2017) P2X7 receptor-dependent tuning of gut epithelial responses to infection. Immunol Cell Biol 95: 178-188. https://doi.org/10.1038/icb.2016.75
    [207] Gu BJ, Wiley JS (2006) Rapid ATP-induced release of matrix metalloproteinase 9 is mediated by the P2X7 receptor. Blood 107: 4946-4953. https://doi.org/10.1182/blood-2005-07-2994
    [208] de Torre-Minguela C, Barbera-Cremades M, Gomez AI, et al. (2016) Macrophage activation and polarization modify P2X7 receptor secretome influencing the inflammatory process. Sci Rep 6: 22586. https://doi.org/10.1038/srep22586
    [209] Csoka B, Nemeth ZH, Toro G, et al. (2015) Extracellular ATP protects against sepsis through macrophage P2X7 purinergic receptors by enhancing intracellular bacterial killing. Faseb j 29: 3626-3637. https://doi.org/10.1096/fj.15-272450
    [210] Wareham KJ, Seward EP (2016) P2X7 receptors induce degranulation in human mast cells. Purinergic Signal 12: 235-246. https://doi.org/10.1007/s11302-016-9497-4
    [211] Kawamura H, Aswad F, Minagawa M, et al. (2006) P2X7 receptors regulate NKT cells in autoimmune hepatitis. J Immunol 176: 2152-2160. https://doi.org/10.4049/jimmunol.176.4.2152
    [212] Martel-Gallegos G, Rosales-Saavedra MT, Reyes JP, et al. (2010) Human neutrophils do not express purinergic P2X7 receptors. Purinergic Signal 6: 297-306. https://doi.org/10.1007/s11302-010-9178-7
    [213] Pelegrin P, Surprenant A (2006) Pannexin-1 mediates large pore formation and interleukin-1beta release by the ATP-gated P2X7 receptor. Embo j 25: 5071-5082. https://doi.org/10.1038/sj.emboj.7601378
    [214] Suh BC, Kim JS, Namgung U, et al. (2001) P2X7 nucleotide receptor mediation of membrane pore formation and superoxide generation in human promyelocytes and neutrophils. J Immunol 166: 6754-6763. https://doi.org/10.4049/jimmunol.166.11.6754
    [215] Tsukimoto M, Maehata M, Harada H, et al. (2006) P2X7 receptor-dependent cell death is modulated during murine T cell maturation and mediated by dual signaling pathways. J Immunol 177: 2842-2850. https://doi.org/10.4049/jimmunol.177.5.2842
    [216] Aswad F, Dennert G (2006) P2X7 receptor expression levels determine lethal effects of a purine based danger signal in T lymphocytes. Cell Immunol 243: 58-65. https://doi.org/10.1016/j.cellimm.2006.12.003
    [217] Scheuplein F, Schwarz N, Adriouch S, et al. (2009) NAD+ and ATP released from injured cells induce P2X7-dependent shedding of CD62L and externalization of phosphatidylserine by murine T cells. J Immunol 182: 2898-2908. https://doi.org/10.4049/jimmunol.0801711
    [218] Albayati S, Vemulapalli H, Tsygankov AY, et al. (2021) P2Y(12) antagonism results in altered interactions between platelets and regulatory T cells during sepsis. J Leukoc Biol 110: 141-153. https://doi.org/10.1002/JLB.3A0220-097R
    [219] Vemulapalli H, Samara A, Tsygankov AY, et al. (2018) Blockade of the P2Y12 signaling pathway with clopidogrel restrains treg proliferation in vivo during sepsis and in Vitro. Blood 132: 2413. https://doi.org/10.1182/blood-2018-99-114884
    [220] Minns MS, Trinkaus-Randall V (2016) Purinergic signaling in corneal wound healing: A tale of 2 receptors. J Ocul Pharmacol Ther 32: 498-503. https://doi.org/10.1089/jop.2016.0009
    [221] Hwang SM, Koo NY, Choi SY, et al. (2009) P2X7 receptor-mediated membrane blebbing in salivary epithelial cells. Korean J Physiol Pharmacol 13: 175-179. https://doi.org/10.4196/kjpp.2009.13.3.175
    [222] Gu BJ, Wiley JS (2018) P2X7 as a scavenger receptor for innate phagocytosis in the brain. Br J Pharmacol 175: 4195-4208. https://doi.org/10.1111/bph.14470
    [223] Okura D, Horishita T, Ueno S, et al. (2015) Lidocaine preferentially inhibits the function of purinergic P2X7 receptors expressed in Xenopus oocytes. Anesth Analg 120: 597-605. https://doi.org/10.1213/ANE.0000000000000585
    [224] North RA (2016) P2X receptors. Philos Trans R Soc Lond B Biol Sci 371. https://doi.org/10.1098/rstb.2015.0427
    [225] Coddou C, Stojilkovic SS, Huidobro-Toro JP (2011) Allosteric modulation of ATP-gated P2X receptor channels. Rev Neurosci 22: 335-354. https://doi.org/10.1515/rns.2011.014
    [226] Coddou C, Yan Z, Obsil T, et al. (2011) Activation and regulation of purinergic P2X receptor channels. Pharmacol Rev 63: 641-683. https://doi.org/10.1124/pr.110.003129
    [227] Sanabria P, Ross E, Ramirez E, et al. (2008) P2Y2 receptor desensitization on single endothelial cells. Endothelium 15: 43-51. https://doi.org/10.1080/10623320802092294
    [228] Schulte G, Fredholm BB (2000) Human adenosine A(1), A(2A), A(2B), and A(3) receptors expressed in Chinese hamster ovary cells all mediate the phosphorylation of extracellular-regulated kinase 1/2. Mol Pharmacol 58: 477-482. https://doi.org/10.1124/mol.58.3.477
    [229] Klaasse EC, Ijzerman AP, de Grip WJ, et al. (2008) Internalization and desensitization of adenosine receptors. Purinergic Signal 4: 21-37. https://doi.org/10.1007/s11302-007-9086-7
    [230] Illes P, Müller CE, Jacobson KA, et al. (2021) Update of P2X receptor properties and their pharmacology: IUPHAR Review 30. Br J Pharmacol 178: 489-514. https://doi.org/10.1111/bph.15299
    [231] Jacobson KA, Delicado EG, Gachet C, et al. (2020) Update of P2Y receptor pharmacology: IUPHAR Review 27. Br J Pharmacol 177: 2413-2433. https://doi.org/10.1111/bph.15005
    [232] Jacobson KA, Muller CE (2016) Medicinal chemistry of adenosine, P2Y and P2X receptors. Neuropharmacology 104: 31-49. https://doi.org/10.1016/j.neuropharm.2015.12.001
    [233] Myers AJ, Eilertson B, Fulton SA, et al. (2005) The purinergic P2X7 receptor Is not required for control of pulmonary Mycobacterium tuberculosis infection. Infect Immun 73: 3192-3195. https://doi.org/10.1128/IAI.73.5.3192-3195.2005
    [234] Santiago-Carvalho I, de Almeida-Santos G, Bomfim CCB, et al. (2021) P2x7 receptor signaling blockade reduces lung inflammation and necrosis during severe experimental tuberculosis. Front Cell Infect Microbiol 11: 672472. https://doi.org/10.3389/fcimb.2021.672472
    [235] Ardissone V, Radaelli E, Zaratin P, et al. (2011) Pharmacologic P2X purinergic receptor antagonism in the treatment of collagen-induced arthritis. Arthritis Rheum 63: 3323-3332. https://doi.org/10.1002/art.30556
    [236] Martinez CG, Zamith-Miranda D, da Silva MG, et al. (2015) P2×7 purinergic signaling in dilated cardiomyopathy induced by auto-immunity against muscarinic M2 receptors: autoantibody levels, heart functionality and cytokine expression. Sci Rep 5: 16940. https://doi.org/10.1038/srep16940
    [237] Baldini C, Santini E, Rossi C, et al. (2017) The P2X7 receptor-NLRP3 inflammasome complex predicts the development of non-Hodgkin's lymphoma in Sjogren's syndrome: a prospective, observational, single-centre study. J Intern Med 282: 175-186. https://doi.org/10.1111/joim.12631
    [238] Baldini C, Rossi C, Ferro F, et al. (2013) The P2X7 receptor-inflammasome complex has a role in modulating the inflammatory response in primary Sjögren's syndrome. J Intern Med 274: 480-489. https://doi.org/10.1111/joim.12115
    [239] Di Virgilio F, Bronte V, Collavo D, et al. (1989) Responses of mouse lymphocytes to extracellular adenosine 5′-triphosphate (ATP). Lymphocytes with cytotoxic activity are resistant to the permeabilizing effects of ATP. J Immunol 143: 1955-1960. https://doi.org/10.4049/jimmunol.143.6.1955
    [240] Filippini A, Taffs RE, Agui T, et al. (1990) Ecto-ATPase activity in cytolytic T-lymphocytes. Protection from the cytolytic effects of extracellular ATP. J Biol Chem 265: 334-340. https://doi.org/10.1016/S0021-9258(19)40234-2
    [241] Falcone C, Caracciolo M, Correale P, et al. (2020) Can adenosine fight COVID-19 acute respiratory distress syndrome?. J Clin Med 9. https://doi.org/10.20944/preprints202007.0426.v1
    [242] Fajgenbaum DC, June CH (2020) Cytokine Storm. N Engl J Med 383: 2255-2273. https://doi.org/10.1056/NEJMra2026131
    [243] Young CNJ, Chira N, Róg J, et al. (2018) Sustained activation of P2X7 induces MMP-2-evoked cleavage and functional purinoceptor inhibition. J Mol Cell Biol 10: 229-242. https://doi.org/10.1093/jmcb/mjx030
    [244] Young CNJ, Górecki DC (2018) P2RX7 purinoceptor as a therapeutic target-the second coming?. Front Chem 6: 248. https://doi.org/10.3389/fchem.2018.00248
    [245] Zhao R, Qiao J, Zhang X, et al. (2019) Toll-like receptor-mediated activation of CD39 internalization in BMDCs leads to extracellular ATP accumulation and facilitates P2X7 receptor activation. Front Immunol 10: 2524. https://doi.org/10.3389/fimmu.2019.02524
    [246] Hotchkiss RS, Monneret G, Payen D (2013) Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis 13: 260-268. https://doi.org/10.1016/S1473-3099(13)70001-X
    [247] Hotchkiss RS, Monneret G, Payen D (2013) Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol 13: 862-874. https://doi.org/10.1038/nri3552
    [248] Ward NS, Casserly B, Ayala A (2008) The compensatory anti-inflammatory response syndrome (CARS) in critically ill patients. Clin Chest Med 29: 617-625. https://doi.org/10.1016/j.ccm.2008.06.010
    [249] Bone RC (1996) Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med 24: 1125-1128. https://doi.org/10.1097/00003246-199607000-00010
    [250] Biscetti L, De Vanna G, Cresta E, et al. (2021) Headache and immunological/autoimmune disorders: a comprehensive review of available epidemiological evidence with insights on potential underlying mechanisms. J Neuroinflammation 18: 259. https://doi.org/10.1186/s12974-021-02229-5
    [251] John S, Hajj-Ali RA (2014) Headache in autoimmune diseases. Headache 54: 572-582. https://doi.org/10.1111/head.12306
    [252] Kim HJ (2021) Pruritus in autoimmune connective tissue diseases. Ann Transl Med 9: 441. https://doi.org/10.21037/atm-20-4894
    [253] Zielinski MR, Systrom DM, Rose NR (2019) Fatigue, sleep, and autoimmune and related disorders. Front Immunol 10: 1827. https://doi.org/10.3389/fimmu.2019.01827
    [254] Morris G, Berk M, Walder K, et al. (2015) Central pathways causing fatigue in neuro-inflammatory and autoimmune illnesses. BMC Med 13: 28. https://doi.org/10.1186/s12916-014-0259-2
    [255] Mifflin KA, Kerr BJ (2017) Pain in autoimmune disorders. J Neurosci Res 95: 1282-1294. https://doi.org/10.1002/jnr.23844
    [256] Lacagnina MJ, Heijnen CJ, Watkins LR, et al. (2021) Autoimmune regulation of chronic pain. Pain Rep 6: e905. https://doi.org/10.1097/PR9.0000000000000905
    [257] Joaquim AF, Appenzeller S (2015) Neuropsychiatric manifestations in rheumatoid arthritis. Autoimmun Rev 14: 1116-1122. https://doi.org/10.1016/j.autrev.2015.07.015
    [258] Shim CH, Cho S, Shin YM, et al. (2022) Emerging role of bystander T cell activation in autoimmune diseases. BMB Rep 55: 57-64. https://doi.org/10.5483/BMBRep.2022.55.2.183
    [259] Fujinami RS, von Herrath MG, Christen U, et al. (2006) Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease. Clin Microbiol Rev 19: 80-94. https://doi.org/10.1128/CMR.19.1.80-94.2006
    [260] van Aalst S, Ludwig IS, van der Zee R, et al. (2017) Bystander activation of irrelevant CD4+ T cells following antigen-specific vaccination occurs in the presence and absence of adjuvant. PLoS One 12: e0177365. https://doi.org/10.1371/journal.pone.0177365
    [261] Bergamaschi L, Mescia F, Turner L, et al. (2021) Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease. Immunity 54: 1257-1275.e1258. https://doi.org/10.1016/j.immuni.2021.05.010
    [262] Lindenbergh MFS, Koerhuis DGJ, Borg EGF, et al. (2019) Bystander T-Cells support clonal T-cell activation by controlling the release of dendritic cell-derived immune-stimulatory extracellular vesicles. Front Immunol 10: 448. https://doi.org/10.3389/fimmu.2019.00448
    [263] Wang JY, Zhang W, Roehrl VB, et al. (2022) An autoantigen atlas from human lung HFL1 cells offers clues to neurological and diverse autoimmune manifestations of COVID-19. Front Immunol 13: 831849. https://doi.org/10.3389/fimmu.2022.831849
    [264] Felipe Cuspoca A, Isaac Estrada P, Velez-van-Meerbeke A (2022) Molecular mimicry of SARS-CoV-2 spike protein in the nervous system: A bioinformatics approach. Comput Struct Biotechnol J 20: 6041-6054. https://doi.org/10.1016/j.csbj.2022.10.022
    [265] Woodruff MC, Ramonell RP, Haddad NS, et al. (2022) Dysregulated naive B cells and de novo autoreactivity in severe COVID-19. Nature 611: 139-147. https://doi.org/10.1038/s41586-022-05273-0
    [266] Milne GR, Palmer TM (2011) Anti-inflammatory and immunosuppressive effects of the A2A adenosine receptor. Sci World J 11: 320-339. https://doi.org/10.1100/tsw.2011.22
    [267] Elsaghir A, El-Sabaa EMW, Ahmed AK, et al. (2023) The role of cluster of differentiation 39 (CD39) and purinergic signaling pathway in viral infections. Pathogens 12. https://doi.org/10.3390/pathogens12020279
    [268] Auclair H, Ouk-Martin C, Roland L, et al. (2019) EBV latency III-transformed B cells are inducers of conventional and unconventional regulatory T cells in a PD-L1-dependent manner. J Immunol 203: 1665-1674. https://doi.org/10.4049/jimmunol.1801420
    [269] Song J-W, Huang H-H, Zhang C, et al. (2019) Expression of CD39 is correlated with HIV DNA levels in naïve tregs in chronically infected ART naïve patients. Front Immunol 10. https://doi.org/10.3389/fimmu.2019.02465
    [270] Gupta PK, Godec J, Wolski D, et al. (2015) CD39 expression identifies terminally exhausted CD8+ T cells. PLoSPathog 11: e1005177. https://doi.org/10.1371/journal.ppat.1005177
    [271] Wingate PJ, McAulay KA, Anthony IC, et al. (2009) Regulatory T cell activity in primary and persistent Epstein-Barr virus infection. J Med Virol 81: 870-877. https://doi.org/10.1002/jmv.21445
    [272] Chevalier MF, Weiss L (2013) The split personality of regulatory T cells in HIV infection. Blood 121: 29-37. https://doi.org/10.1182/blood-2012-07-409755
    [273] Wang L, Qiu J, Yu L, et al. (2014) Increased numbers of CD5+CD19+CD1dhighIL-10+ Bregs, CD4+Foxp3+ Tregs, CD4+CXCR5+Foxp3+ follicular regulatory T (TFR) cells in CHB or CHC patients. J Transl Med 12: 251. https://doi.org/10.1186/s12967-014-0251-9
    [274] Cash E, Goodwin AT, Tatler AL (2023) Adenosine receptor signalling as a driver of pulmonary fibrosis. Pharmacol Ther 249: 108504. https://doi.org/10.1016/j.pharmthera.2023.108504
    [275] Fausther M (2018) Extracellular adenosine: a critical signal in liver fibrosis. Am J Physiol Gastrointest Liver Physiol 315: G12-G19. https://doi.org/10.1152/ajpgi.00006.2018
    [276] Sheng G, Chen P, Wei Y, et al. (2020) Viral infection increases the risk of idiopathic pulmonary fibrosis: A meta-analysis. Chest 157: 1175-1187. https://doi.org/10.1016/j.chest.2019.10.032
    [277] Androutsakos T, Schina M, Pouliakis A, et al. (2020) Causative factors of liver fibrosis in HIV-infected patients. A single center study. BMC Gastroenterol 20: 91. https://doi.org/10.1186/s12876-020-01230-1
    [278] McCaughan GW, George J (2004) Fibrosis progression in chronic hepatitis C virus infection. Gut 53: 318-321. https://doi.org/10.1136/gut.2003.026393
    [279] Rockey DC, Friedman SL (2021) Fibrosis regression after eradication of hepatitis C virus: From bench to bedside. Gastroenterology 160: 1502-1520.e1501. https://doi.org/10.1053/j.gastro.2020.09.065
    [280] Stock TC, Bloom BJ, Wei N, et al. (2012) Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate. J Rheumatol 39: 720-727. https://doi.org/10.3899/jrheum.110874
    [281] Keystone EC, Wang MM, Layton M, et al. (2012) Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine. Ann Rheum Dis 71: 1630-1635. https://doi.org/10.1136/annrheumdis-2011-143578
    [282] Recourt K, de Boer P, van der Ark P, et al. (2023) Characterization of the central nervous system penetrant and selective purine P2X7 receptor antagonist JNJ-54175446 in patients with major depressive disorder. Transl Psychiatry 13: 266. https://doi.org/10.1038/s41398-023-02557-5
    [283] Tamargo J, Le Heuzey JY, Mabo P (2015) Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide. Eur J Clin Pharmacol 71: 549-567. https://doi.org/10.1007/s00228-015-1832-0
    [284] Eser A, Colombel JF, Rutgeerts P, et al. (2015) Safety and efficacy of an oral inhibitor of the purinergic receptor P2X7 in adult patients with moderately to severely active crohn's disease: A randomized placebo-controlled, double-blind, phase IIa study. Inflamm Bowel Dis 21: 2247-2253. https://doi.org/10.1097/MIB.0000000000000514
    [285] Neves AR, Castelo-Branco MT, Figliuolo VR, et al. (2014) Overexpression of ATP-activated P2X7 receptors in the intestinal mucosa is implicated in the pathogenesis of Crohn's disease. Inflamm Bowel Dis 20: 444-457. https://doi.org/10.1097/01.MIB.0000441201.10454.06
  • This article has been cited by:

    1. Christian Cortés García, Jasmidt Vera Cuenca, Additive Allee effect on prey in the dynamics of a Gause predator–prey model with constant or proportional refuge on prey at low or high densities, 2023, 126, 10075704, 107427, 10.1016/j.cnsns.2023.107427
    2. Christian Cortés-García, Population dynamics in a Leslie-Gower predator-prey model with proportional prey refuge at low densities, 2025, 543, 0022247X, 128993, 10.1016/j.jmaa.2024.128993
    3. Christian Cortés García, Population dynamics in a Leslie–Gower predator–prey model with predator harvesting at high densities, 2024, 0170-4214, 10.1002/mma.10359
    4. Christian Cortés-García, Dynamics in a Filippov–Gause Predator–Prey Model with Hunting Cooperation or Competition Among Predators for High or Low Prey Densities, 2025, 35, 0218-1274, 10.1142/S0218127425500142
  • Reader Comments
  • © 2024 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(1550) PDF downloads(122) Cited by(0)

Figures and Tables

Figures(4)  /  Tables(2)

Other Articles By Authors

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog